Document:

exv10w60

 

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

EXHIBIT 10.60

PRIVILEGED AND CONFIDENTIAL

EXECUTION COPY

ASSET PURCHASE AGREEMENT

by and among

INTERMUNE, INC.

(the “Buyer”),

KDL GmbH

(“KDL GmbH”)

and

DR. SHITOTOMO YAMAUCHI

(“Dr. Yamauchi” and, collectively with KDL GmbH, the “Sellers”)

Dated as of November 21, 2007

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	Section	 	Page
	 
	 	 	 	 
	ARTICLE 1 DEFINITIONS
	 	 	1	 
	 
	 	 	 	 
	Section 1.1 Defined Terms
	 	 	1	 
	Section 1.2 Construction
	 	 	8	 
	 
	 	 	 	 
	ARTICLE 2 THE TRANSACTION
	 	 	9	 
	 
	 	 	 	 
	Section 2.1 Transfer of Purchased Assets
	 	 	9	 
	Section 2.2 Excluded Assets
	 	 	9	 
	Section 2.3 Assumed Liabilities
	 	 	9	 
	Section 2.4 Excluded Liabilities
	 	 	9	 
	Section 2.5 Purchase Price
	 	 	10	 
	Section 2.6 Risk of Loss
	 	 	11	 
	Section 2.7 Allocation
	 	 	11	 
	 
	 	 	 	 
	ARTICLE 3 CLOSING
	 	 	12	 
	 
	 	 	 	 
	Section 3.1 Closing
	 	 	12	 
	Section 3.2 Closing Deliveries by the Sellers
	 	 	12	 
	Section 3.3 Closing Deliveries and Payments by the Buyer
	 	 	13	 
	Section 3.4 Closing Deliveries by the Buyer and the Sellers
	 	 	13	 
	Section 3.5 Liabilities Related to Finders’ or Brokers’ Fees
	 	 	13	 
	Section 3.6 Further Actions
	 	 	13	 
	Section 3.7 Withholdings
	 	 	14	 
	 
	 	 	 	 
	ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF THE SELLERS
	 	 	14	 
	 
	 	 	 	 
	Section 4.1 Organization and Authority
	 	 	14	 
	Section 4.2 Title to Purchased Assets
	 	 	14	 
	Section 4.3 Consents; No Violations
	 	 	14	 
	Section 4.4 Compliance with Laws and Litigation
	 	 	15	 
	Section 4.5 Contracts
	 	 	15	 
	Section 4.6 Tax Matters
	 	 	15	 
	Section 4.7 Intellectual Property
	 	 	15	 
	Section 4.8 Product Records
	 	 	17	 
	Section 4.9 Brokers, Finders, etc
	 	 	17	 
	Section 4.10 No Other Agreements to Sell the Purchased Assets
	 	 	17	 
	Section 4.11 Disclosure
	 	 	17	 
	Section 4.12 Disclaimer of Implied Warranty
	 	 	17	 
	Section 4.13 Regulatory Matters
	 	 	18	 
	 
	 	 	 	 
	ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF BUYER
	 	 	18	 
	 
	 	 	 	 
	Section 5.1 Organization and Authority
	 	 	18	 
	Section 5.2 Consents; No Violations
	 	 	19	 
	Section 5.3 Brokers, Finders, etc
	 	 	19	 
	 
	 	 	 	 
	ARTICLE 6 CERTAIN OTHER COVENANTS
	 	 	19	 
	 
	 	 	 	 
	Section 6.1 Cooperation
	 	 	19	 
	Section 6.2 Billing and Invoices
	 	 	20	 
	Section 6.3 Covenant Not To Compete
	 	 	20	 

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

 

	 	 	 	 	 
	Section	 	Page
	 
	 	 	 	 
	Section 6.4 Exclusive License; Right of First Refusal
	 	 	21	 
	Section 6.5 Tax Matters
	 	 	22	 
	Section 6.6 Notice to Third Parties
	 	 	24	 
	Section 6.7 Patent Maintenance
	 	 	24	 
	 
	 	 	 	 
	ARTICLE 7 CONDITIONS TO CLOSING
	 	 	24	 
	 
	 	 	 	 
	Section 7.1 Conditions Precedent to Buyer’s Obligations
	 	 	24	 
	Section 7.2 Conditions Precedent to Sellers’ Obligations
	 	 	25	 
	 
	 	 	 	 
	ARTICLE 8 INDEMNIFICATION
	 	 	26	 
	 
	 	 	 	 
	Section 8.1 Survival of Representations and Warranties
	 	 	26	 
	Section 8.2 Indemnification
	 	 	27	 
	Section 8.3 Right of Setoff
	 	 	28	 
	 
	 	 	 	 
	ARTICLE 9 MISCELLANEOUS PROVISIONS
	 	 	28	 
	 
	 	 	 	 
	Section 9.1 Confidentiality and Publicity
	 	 	28	 
	Section 9.2 Notices
	 	 	29	 
	Section 9.3 Governing Law
	 	 	30	 
	Section 9.4 Representation By Counsel
	 	 	30	 
	Section 9.5 Expenses
	 	 	31	 
	Section 9.6 Entire Agreement
	 	 	31	 
	Section 9.7 Amendment; Waiver
	 	 	31	 
	Section 9.8 Severability
	 	 	31	 
	Section 9.9 Assignment
	 	 	31	 
	Section 9.10 Counterparts
	 	 	31	 
	Section 9.11 Waiver of Jury Trial
	 	 	31	 
	Section 9.12 Consent to Jurisdiction
	 	 	32	 
	Section 9.13 Attorney Fees
	 	 	32	 
	Section 9.14 Remedies Cumulative; Specific Performance
	 	 	32	 
	Section 9.15 Time is of Essence
	 	 	32	 
	Section 9.16 Executory Nature of the Duties Imposed by this Agreement
	 	 	32	 
	Section 9.17 Bankruptcy Rights
	 	 	32	 
	Section 9.18 Release
	 	 	32	 

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

 

PRIVILEGED AND CONFIDENTIAL

EXECUTION COPY

ASSET PURCHASE AGREEMENT

(KDL Agreement)

     This ASSET PURCHASE AGREEMENT (as amended from time to time, the “Agreement”), dated
November 21, 2007, is made and entered into by and among InterMune, Inc., a Delaware corporation
(the “Buyer”), KDL GmbH, a Swiss corporation (“KDL GmbH”), and Dr. Shitotomo
Yamauchi (“Dr. Yamauchi” and, collectively with KDL GmbH, the “Sellers”). The
Buyer and the Sellers are sometimes collectively referred to herein as the “Parties” and
individually as a “Party.”

RECITALS

     WHEREAS, the Buyer, the Sellers, KDL, Inc. (“KDL Japan”), Marnac, Inc. (“Marnac”), and
Dr. Solomon B. Margolin (“Dr. Margolin” and, collectively with the Sellers, KDL Japan and
Marnac, the “Licensors”) are parties to that certain License Agreement dated as of March
29, 2002, as amended (the “Existing License Agreement”), pursuant to which the Licensors
granted to the Buyer certain limited rights and licenses related to anti-fibrotic uses of
Pirfenidone on a worldwide basis (except for Japan, Taiwan and Korea);

     WHEREAS, Marnac and KDL Japan are parties to that certain License Agreement dated November 5,
1996 (the “Shionogi License Agreement”) with Shionogi & Co., Ltd. (“Shionogi”)
pursuant to which Marnac and KDL Japan have granted to Shionogi certain limited rights and licenses
related to anti-fibrotic uses of Pirfenidone within Japan, Taiwan and Korea;

     WHEREAS, the Buyer, Marnac and Dr. Margolin have entered into an Asset Purchase Agreement,
dated as of November 19, 2007 and certain related agreements pursuant to which, among other things,
the Buyer acquired from Marnac and Dr. Margolin certain assets related to Pirfenidone; and

     WHEREAS, the Sellers desire to sell certain assets related to Pirfenidone to the Buyer, and
the Buyer desires to purchase such assets from the Sellers, on the terms and subject to conditions
set forth herein.

     NOW, THEREFORE, in consideration of the promises, representations, warranties, covenants and
agreements contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereto, intending to be legally bound hereby, agree
as follows:

ARTICLE 1

DEFINITIONS

     Section 1.1 Defined Terms. For the purposes of this Agreement, the following words and phrases shall have the following
meanings whether in the singular or the plural:

     “Action” shall mean any action, claim, suit, litigation, proceeding, labor dispute,
arbitral action, governmental audit, inquiry, criminal prosecution, examination, investigation or
unfair labor practice charge or complaint commenced, brought, conducted or heard at law or in
equity or before any Governmental Authority or any arbitrator or arbitral panel.

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-1-

 

     “Affiliate” shall mean any company or entity controlled by, controlling or under
common control with a Party. As used in the definition of “Affiliate,” “control” means (a) that
Person owns, directly or indirectly, more than fifty percent (50%) of the voting stock of another
entity, or (b) that a Person has the actual ability to control and direct the management of the
entity, whether by contract or otherwise.

     “Agreement” shall have the meaning set forth in the first paragraph of this Agreement.

     “Allocation” shall have the meaning set forth in Section 2.7.

     “Ancillary Agreements” shall mean, collectively, the Bill of Sale, the Assignment and
Assumption Agreement and the IP Assignments.

     “Approval Notice and Report” shall have the meaning set forth in Section
6.4(c).

     “Assignment and Assumption Agreement” shall have the meaning set forth in Section
3.4(a).

     “Assumed Contracts” shall have the meaning set forth in the definition of Purchased
Assets.

     “Assumed Liabilities” shall have the meaning set forth in Section 2.3.

     “Bill of Sale” shall have the meaning set forth in Section 3.2(a).

     “Business Day” means a day, which is not a Saturday, a Sunday, or a statutory holiday
in the United States.

     “Buyer” shall have the meaning set forth in the first paragraph of this Agreement.

     “Buyer Disclosure Schedule” shall have the meaning set forth in the first paragraph of
Article 5.

     “Buyer Proprietary Information” shall have the meaning set forth in Section
9.1(b).

     “CAPACITY Trial” shall mean (i) the randomized, double-blind, placebo controlled,
Phase III, three-arm study of the safety and efficacy of Pirfenidone in patients with idiopathic
pulmonary fibrosis under protocol PIPF-004; and (ii) the randomized, double-blind, placebo
controlled, Phase III study of the safety and efficacy of Pirfenidone in patients with idiopathic
pulmonary fibrosis under protocol PIPF-006, in each case as designed by and initiated by the Buyer.

     “Claim” shall have the meaning set forth in Section 8.2(c).

     “Claim Notice” shall have the meaning set forth in Section 8.2(c).

     “Closing” shall have the meaning set forth in Section 3.1.

     “Closing Date” shall have the meaning set forth in Section 3.1.

     “Closing Payment” shall have the meaning set forth in Section 2.5(a).

     “Code” means the United States Internal Revenue Code of 1986, as amended.

     “Competing Product” shall mean any product that contains Pirfenidone. Notwithstanding
the foregoing, Competing Product shall not include those products containing Pirfenidone that (i)
are

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-2-

 

designed, marketed, sold and used exclusively for [ * ]indications (excluding [ * ]) and (ii)
are covered by a pending or issued claim of USPTO Application No. [ * ], U.S. Patent No. [ * ], PCT
Application No. [ * ], PCT Application No. [ * ], [ * ] or [ * ], or any patent applications,
provisional patent applications or similar instruments (including any and all substitutions,
divisions, continuations, reissues, renewals, extensions, reexaminations, patents of addition,
supplementary protection certificates, inventors’ certificates, pediatric data package exclusivity
extensions, or the like) as well as any foreign equivalents thereof (including certificates of
invention and any applications therefor). Competing Product shall also exclude any product in
Japan, Korea or Taiwan that currently is or is in the future under license of the Shionogi Assets
(and any such product shall continue to be excluded from the definition of a Competing Product
after it ceases to be under license of the Shionogi Assets).

     “Confidentiality Agreement” shall have the meaning set forth in Section 9.1.

     “Consents” shall have the meaning set forth in Section 4.3(a).

     “Contract” shall mean any agreement, contract, lease, purchase, under, consensual
obligation, promise, or undertaking, obligation or commitment (whether written or oral), to which
one or more of the Sellers are a party that is primarily related to the Product, the Product
Business, the Purchased Assets or the Assumed Liabilities, or which is necessary for the conduct of
the Product Business to the extent conducted by the Sellers.

     “Copyrights” shall have the meaning set forth in the definition of Purchased Assets.

     “Damages” shall have the meaning set forth in Section 8.2(a).

     “Diligence Period” shall have the meaning set forth in Section 6.4(c).

     “Dollar(s)” shall mean the USA dollar(s).

     “Dr. Yamauchi” shall have the meaning set forth in the first paragraph of this
Agreement.

     “EMEA” means the European Medicines Evaluation Agency.

     “Encumbrance” shall mean claims, security interests, liens, pledges, charges, escrows,
options, proxies, rights of first refusal, preemptive rights, mortgages, hypothecations,
assessments, prior assignments, title retention agreements, conditional sales agreements,
indentures, deeds of trust, leases, levies or security agreements of any kind whatsoever imposed
upon the subject property or item.

     “Excluded Assets” notwithstanding any other provision of this Agreement, shall mean
all assets and properties of the Sellers, in the territory of Japan, Taiwan, and Korea, other than
the Purchased Assets, including USPTO Application No. [ * ]; U.S. Patent No. [ * ]; PCT Application
No. [ * ]; PCT Application No. [ * ]; [ * ]; [ * ]; [ * ] (application Number); and the Shionogi
Assets.

     “Excluded Liabilities” shall mean all Liabilities or obligations of the Sellers (other
than the Assumed Liabilities), including any obligation or Liability of the Sellers created as a
result of this Agreement and those items set forth on Schedule 2.4(a).

     “Existing License Agreement” shall have the meaning set forth in the first sentence of
the Recitals.

     “FDA” means the United States Food and Drug Administration.

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-3-

 

     “Governmental Authority” shall mean any (a) nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state,
local, municipal, foreign or other government; or (c) governmental or quasi-governmental authority
of any nature (including any governmental division, department, agency, commission,
instrumentality, board, bureau, official, ministry, organization, unit, body or entity and any
court or other tribunal).

     “IND” shall mean an Investigational New Drug Application (as defined under the United
States Food, Drug and Cosmetic Act and applicable Regulations promulgated thereunder).

     “Indemnified Party” shall have the meaning set forth in Section 8.2(c).

     “Indemnifying Party” shall have the meaning set forth in Section 8.2(c).

     “Intellectual Property” shall mean Copyrights, Know-How, Trademarks, Patents, and all
other intellectual property or proprietary rights, in each case whether or not subject to statutory
registration or protection.

     “IP Assignments” shall have the meaning set forth in Section 3.2(b).

     “IRS” means the United States Internal Revenue Service.

     “KDL GmbH” shall have the meaning set forth in the first paragraph of this Agreement.

     “KDL Japan” shall have the meaning set forth in the first sentence of the Recitals.

     “Know-How” shall have the meaning set forth in the definition of Purchased Assets.

     “Knowledge of the Sellers” or “to the Sellers’ Knowledge” or any similar such
statement with respect to the Sellers shall mean the best actual knowledge of any executive officer
or director of KDL GmbH, any key employee of KDL GmbH directly involved in the management,
operation or research and development of the Purchased Assets, or Dr. Yamauchi.

     “Law” shall mean any constitution, law, statute, treaty, role, directive, requirement
or Regulation or Order of any Governmental Authority.

     “Liability” shall mean, collectively, any indebtedness, guaranty, endorsement,
commitment, claim, loss, damage, deficiency, cost, expense, obligation or responsibility, fixed or
unfixed, known or unknown, choate or inchoate, liquidated or unliquidated, secured or unsecured,
direct or indirect, matured or unmatured, or absolute, contingent or otherwise, including any
product liability.

     “Licensors” shall have the meaning set forth in the first sentence of the recitals.

     “MAA Milestone Payment” shall have the meaning set forth in Section
2.5(b)(iii).

     “Milestone Payments” shall mean, collectively, the Phase III Milestone Payment, the
NDA Milestone Payment and the MAA Milestone Payment.

     “NDA Milestone Payment” shall have the meaning set forth in Section
2.5(b)(ii).

     “Non-Income Taxes” shall mean (i) any real property, personal property, ad valorem and
other similar Taxes and (ii) any sales, use, transaction, excise and other similar Taxes;
provided, however, that

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-4-

 

“Non-Income Taxes” shall not include (a) any Taxes that are income Taxes or Taxes in the
nature of income Taxes or (b) any Transfer Taxes.

     “Officer’s Certificate” shall have the meaning set forth in Section 3.2(d).

     “Order” shall mean any: (a) temporary, preliminary or permanent order, judgment,
injunction, edict, decree, ruling, pronouncement, proclamation, directive, determination, decision,
opinion, verdict, sentence, stipulation, subpoena, writ or award that is or has been issued, made,
entered, rendered or otherwise put into effect by or under the authority of any court,
administrative agency or other Governmental Authority; or (b) Contract with any Governmental
Authority that is or has been entered into in connection with any Action.

     “[ * ]” shall mean [ * ].

     “Other Party” shall have the meaning set forth in Section 6.5(e)(iii).

     “Party” or “Parties” shall have the meaning set forth in the first paragraph
of this Agreement.

     “Patents” shall have the meaning set forth in the definition of Purchased Assets.

     “Permitted Encumbrances” shall mean liens imposed by any Governmental Authority for
Taxes not yet due and payable.

     “Person” shall mean any natural person, corporation, unincorporated organization,
partnership, association, joint stock company, joint venture, limited liability company, trust or
entity or organization of any kind or Governmental Authority.

     “Phase III Milestone Payment” shall have the meaning set forth in Section
2.5(b)(i).

     “Pirfenidone” shall mean that certain substance whose chemical composition is
5-methyl-1-phenyl-2-(1H)-pyridone (CAS 53179-13-8).

     “Post-Closing Tax Period” shall mean any Tax Period beginning after the close of
business on the Closing Date and the portion of any Straddle Period beginning after the Closing
Date.

     “Pre-Closing Tax Period” shall mean any Tax Period ending on or before the close of
business on the Closing Date and the portion of any Straddle Period ending on the Closing Date.

     “Patent Transferor” shall have the meaning set forth in Section 6.4(a).

     “Product” shall mean any pharmaceutical composition or preparation, in any dosage,
strength or size, containing Pirfenidone.

     “Product Business” shall mean the manufacturing, using, developing, promoting,
selling, offering to sell, or importing of Pirfenidone for sale to the extent currently being or
previously conducted by the Sellers.

     “Product Copyrights” shall have the meaning set forth in the definition of Purchased
Assets.

     “Product Data” shall have the meaning set forth in the definition of Purchased Assets.

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-5-

 

     “Product Intellectual Property” shall have the meaning set forth in the definition of
Purchased Assets.

     “Product Know-How” shall have the meaning set forth in the definition of Purchased
Assets.

     “Product Patents” shall have the meaning set forth in the definition of Purchased
Assets.

     “Product Records” shall have the meaning set forth in the definition of Purchased
Assets.

     “Product Trademarks” shall have the meaning set forth in the definition of Purchased
Assets.

     “Purchased Assets” shall mean, collectively: (i) the Contracts or portions of the
Contracts set forth on Schedule 1.1(a) (the “Assumed Contracts”); (ii) as primarily
related to Pirfenidone, all permits, licenses, certificates, approvals, Product Registrations,
waivers, exemptions, qualifications, consents or orders of, filings and authorizations issued by
any Governmental Authority to the Sellers or their Representatives, if any (the “Regulatory
Approvals”); (iii) all toxicology, pre-clinical, clinical and manufacturing information and
data, including with respect to clinical trials, and all submissions and correspondence with or to
any Governmental Authority regarding the Product, including all validation data and documentation
supporting the process of manufacturing the Product, but only to the extent the foregoing may be in
the possession or control of any Seller (or any Affiliate of any Seller) (the “Product
Data”); (iv) all domestic and foreign copyrights, copyright registrations, copyright
applications, original works of authorship fixed in any tangible medium of expression, including
literary works (including all forms and types of computer software, including all source code,
object code, firmware, development tools, files, records and data, and all documentation related to
any of the foregoing), pictorial, and graphic works relating to the Product Data and Product
Records (“Copyrights”), except for any Copyrights to published scientific papers,
unpublished academic materials, and submitted but unpublished scientific papers of KDL GmbH,
including those by Dr. Yamauchi or other KDL GmbH employees, as owned, licensed, sublicensed or
otherwise controlled by any Seller and primarily related to Pirfenidone (“Product
Copyrights”); (v) trade secrets, technology, discoveries and improvements, know-how,
proprietary rights, formulae, confidential and proprietary information, technical information,
techniques, inventions, designs, drawings, procedures, processes, models, formulations, manuals and
systems, whether or not patentable or copyrightable, including all biological, chemical,
biochemical, toxicological, pharmacological and
metabolic material and information and data relating thereto and formulation, clinical,
analytical and stability information and data which have actual or potential commercial value and
are not available in the public domain (“Know-How”) as owned, licensed, sublicensed or
otherwise controlled by any Seller, if any, and primarily related to Pirfenidone, including as
developed in connection with clinical trials (“Product Know-How”); (vi) the United States
patents, patent applications, provisional patent applications and similar instruments (including
any and all substitutions, divisions, continuations, continuations-in-part, reissues, renewals,
extensions, reexaminations, patents of addition, supplementary protection certificates, inventors’
certificates, pediatric data package exclusivity extensions, or the like) as well as any foreign
equivalents of the foregoing (including certificates of invention and any applications therefor)
(“Patents”) as owned (in whole or in part), licensed, sublicensed or otherwise controlled
by any Seller and primarily related to Pirfenidone (“Product Patents”); (vii) all domestic
and foreign trademarks, trademark registrations, trademark applications, service marks, service
mark registrations, service mark applications, business marks, brand names, trade names, names,
internet domains and URLs, and all goodwill associated therewith, if any (“Trademarks”) as
owned, licensed, sublicensed or otherwise controlled by any Seller and primarily related to
Pirfenidone (“Product Trademarks” and, collectively with Product Copyrights, Product
Know-How and Product Patents, “Product Intellectual Property”); and (viii) all files,
documents, instruments, papers, books and records owned or controlled by any Seller, whether in
electronic or tangible form, to the extent relating to the Purchased Assets, including any research
and development files, marketing materials (if any), regulatory files, adverse event reports and

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-6-

 

files, clinical studies and all documentation relating to the Product Intellectual Property,
but excluding any such items to the extent that any applicable Law prohibits their transfer (the
“Product Records”). The Parties agree that “Purchased Assets” does not include any of the
Excluded Assets.

     “Product Registrations” shall mean all applications, all Investigational New Drug
Applications (INDs) and their foreign equivalents, new drug applications, abbreviated new drug
applications, new drug submissions, and any comparable applications and submissions, together with
any and all supplements or modifications or amendments thereto, whether existing, pending,
withdrawn or in draft form, together with all correspondence to or from any Governmental Authority
with respect thereto, prepared and submitted to any Governmental Authority with respect to any
Product.

     “Purchase Price” shall have the meaning set forth in Section 2.5.

     “Recipient Party” shall have the meaning set forth in Section 6.5(e)(iii).

     “Regulations” shall mean any laws, statutes, ordinances, regulations, rules, notice
requirements, court decisions, agency guidelines, principles of Law and orders of any foreign,
federal, state or local Governmental Authority.

     “Regulatory Approvals” shall have the meaning set forth in the definition of Purchased
Assets.

     “Released Claims” shall have the meaning set forth in Section 9.18.

     “Representative” shall mean any officer, director, principal, attorney, accountant,
agent, employee or other representative of any Person.

     “Restricted Territory” means the entire world.

     “Right of First Refusal” shall have the meaning set forth in Section 6.4(d).

     “ROFR Notice” shall have the meaning set forth in Section 6.4(d).

     “Schedules” shall refer to the schedules to this Agreement which are hereby
incorporated by reference into this Agreement.

     “SEC” means the Securities and Exchange Commission.

     “Sellers” shall have the meaning set forth in the first paragraph of this Agreement.

     “Sellers Disclosure Schedule” shall have the meaning set forth in the first paragraph
of Article 4.

     “Sellers Proprietary Information” shall have the meaning set forth in Section
9.1(c).

     “Shionogi” shall have the meaning set forth in the second sentence of the Recitals.

     “Shionogi Assets” shall mean the Shionogi License Agreement and [ * ] and other
Japanese patents and patent applications disclosing and claiming certain [ * ], as well as any and
all divisions, re-issues, continuations, substitutes and extension in part or all of such patents
or patent applications which are [ * ].

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-7-

 

     “Shionogi License Agreement” shall have the meaning set forth in the second sentence
of the Recitals.

     “Straddle Period” shall mean any Tax Period beginning before and ending after the
Closing Date.

     “Survival Date” shall have the meaning set forth in Section 8.1(a).

     “Taxes” mean any federal, state, local, foreign or other tax, levy, impost, fee,
assessment or other government charge, including without limitation income, estimated income,
business, occupation, franchise, property, payroll, personal property, sales, transfer, use,
employment, commercial rent, occupancy, franchise or withholding taxes, and any premium, including
without limitation interest, penalties and additions in connection therewith.

     “Tax Period” shall mean any period prescribed by any Governmental Authority for which
a Tax Return is required to be filed or a Tax is required to be paid.

     “Tax Return” shall mean any return, declaration, report, claim for refund, or
information return or statement relating to Taxes, including any schedule or attachment thereto,
and including any amendment thereof.

     “Trademarks” shall have the meaning set forth in the definition of Purchased Assets.

     “Transfer Taxes” shall mean all transfer, documentary, sales, use, stamp,
registration, value added and other such Taxes and fees (including any penalties and interest)
incurred in connection with this Agreement and the transactions contemplated hereby.

     “Treasury Regulations” shall mean the income tax regulations issued under the Code.

     Section 1.2 Construction.

     (a) The words “hereof,” “herein” and “hereunder” and words of similar import when used in this
Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement,
and Article, Section, Schedule and Exhibit references are to this Agreement unless otherwise
specified. The meaning of defined terms shall be equally applicable to the singular and plural
forms of the defined terms. The terms “include” and “including” and variations thereof, are not
limiting but rather shall be deemed to be followed by the words “without limitation.”

     (b) References to agreements and other documents shall be deemed to include all subsequent
amendments and other modifications thereto.

     (c) References to statutes shall include all regulations promulgated thereunder and references
to statutes or regulations shall be construed as including all statutory and regulatory provisions
consolidating, amending or replacing the statute or regulation.

     (d) References to “license” or “licenses” shall include “sublicense” or “sublicenses,” as
applicable.

     (e) The captions, titles and headings of this Agreement are for convenience of reference only
and shall not affect the construction of this Agreement.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-8-

 

     (f) Whenever the context requires: the singular number shall include the plural, and vice
versa; the masculine gender shall include the feminine and neuter genders; the feminine gender
shall include the masculine and neuter genders; and the neuter gender shall include the masculine
and feminine genders

     (g) The Parties participated jointly in the negotiation and drafting of this Agreement and the
language used in this Agreement shall be deemed to be the language chosen by the Parties to express
their mutual intent. If an ambiguity or question of intent or interpretation arises, then this
Agreement will accordingly be construed as drafted jointly by the Parties to this Agreement, and no
presumption or burden of proof will arise favoring or disfavoring any Party to this Agreement by
virtue of the authorship of any of the provisions of this Agreement.

     (h) The Schedules and Exhibits to this Agreement are a material part hereof and shall be
treated as if fully incorporated into the body of this Agreement.

ARTICLE 2

THE TRANSACTION

     Section 2.1 Transfer of Purchased Assets. At the Closing, upon the terms and subject to the conditions hereof and in reliance upon the
representations, warranties and covenants contained herein and in consideration of the Purchase
Price paid and to be paid to the Sellers by the Buyer, the Sellers will sell, convey, transfer, assign
and deliver to the Buyer, and the Buyer will purchase, take delivery of and acquire from the
Sellers, all of the Sellers’ right, title and interest in and to the Purchased Assets, free and
clear of any Encumbrances, except for Permitted Encumbrances.

     Section 2.2 Excluded Assets. The Parties acknowledge and agree that the Sellers are not selling, conveying, transferring,
delivering or assigning any rights whatsoever to the Excluded Assets to the Buyer, and the Buyer is
not purchasing, taking delivery of or acquiring any rights whatsoever to the Excluded Assets from
the Sellers.

     Section 2.3 Assumed Liabilities. As of the Closing Date, the Buyer shall assume and agree to pay, perform or otherwise discharge,
in accordance with their respective terms and subject to the respective conditions thereof, only
the following Liabilities (collectively, the “Assumed Liabilities”):

     (a) Any Liability arising after the Closing Date under any Assumed Contract (other than any
Liability arising out of or relating to a breach of, or default under, such Assumed Contract which
occurred or prior to the Closing Date); and

     (b) Any other Liability specifically set forth on Schedule 2.3(b) hereto.

For the avoidance of doubt, nothing in this Section 2.3 is intended to, or shall be
interpreted to, limit or otherwise reduce the Liabilities of the Buyer as they may occur and/or
exist after the Closing Date solely by virtue of the Buyer’s ownership, marketing or use of the
Purchased Assets, but rather, this Section 2.3 is solely intended to identify and provide
for the assumption by the Buyer of those Liabilities of the Sellers that are specifically assumed
by the Buyer hereunder and which, but for such assumption, would remain Liabilities of the Sellers.

     Section 2.4 Excluded Liabilities. Notwithstanding any other provision of this Agreement, except for the Assumed Liabilities
expressly assumed in Section 2.3, the Buyer shall not assume, or

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-9-

 

otherwise be responsible for, any Liabilities of any Seller or any of their respective Affiliates,
whether liquidated or unliquidated, or known or unknown, whether arising out of occurrences prior
to, at or after the Closing Date (“Excluded Liabilities”), which Excluded Liabilities shall
include:

     (a) any Liability of any Seller that arises out of or relates to any Excluded Assets (for the
avoidance of doubt, the Parties agree that any Liabilities of Marnac and KDL Japan under the
Shionogi License Agreement shall remain the Liabilities of Marnac and KDL Japan and are Excluded
Liabilities);

     (b) any Liability of any Seller under or with respect to any Contract (other than an Assumed
Contract pursuant to Section 2.3(a));

     (c) any Liability of any Seller arising out of or related to any Action asserted on or prior
to the Closing Date against any Seller, or against or in respect of any Purchased Asset or the
conduct of the Product Business, or the basis of which shall have arisen on or prior to the Closing
Date;

     (d) any Liability arising from any injury to or death of any Person or damage to or
destruction of any property, whether based on negligence, breach of warranty, strict liability,
enterprise liability or any other legal or equitable theory arising from defects in products
manufactured or services performed by or on behalf of any Seller or any other Person on or prior to
the Closing Date;

     (e) any Liability of any Seller arising out of or relating to the ownership or operation of
the Purchased Assets and/or the Product Business prior to Closing, including any claims,
obligations, rebates or litigation arising out of or relating to events or conditions occurring
prior to Closing or Products sold by any Seller prior to Closing;

     (f) any Liability to the extent arising out of or as a result of the conduct of any business
of the Sellers and their respective Affiliates other than those liabilities expressly assumed
herein pursuant to Section 2.3;

     (g) any Liability arising out of or relating to any finder’s fee, brokerage fee, commission or
similar payment in connection with any Seller’s entry into this Agreement or the consummation of
the transactions contemplated hereby, including any of the Contracts listed on Section 4.9
of the Sellers Disclosure Schedule; and

     (h) any Liability of any Seller, or any member of any consolidated, affiliated, combined or
unitary group of which any Seller is or has been a member, for any Tax, and any Liability for Taxes
attributable to the Purchased Assets or the Product Business for any Pre-Closing Tax Period.

     Section 2.5 Purchase Price. In consideration for the sale, transfer, conveyance, assignment and delivery of the Purchased
Assets and the execution and delivery of this Agreement and the Ancillary Agreements by the
Sellers, upon the terms and subject to the conditions set forth in this Agreement (collectively,
the “Purchase Price”):

     (a) Closing Payment. At the Closing, the Buyer shall (i) deliver (or cause to be
delivered) to the Sellers an upfront payment in the form of a payment, which shall be nonrefundable
for any reason whatsoever, in the aggregate amount of $4,250,000 in cash, payable by wire transfer
in immediately available funds in the allocations and to the accounts specified in Schedule
2.5 (the “Closing Payment”); and (ii) assume the Assumed Liabilities pursuant to
Section 2.3.

     (b) Milestone Payments. Subject to Article 8:

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-10-

 

          (i) By [ * ], the Buyer shall notify the Sellers of its decision, in the Buyer’s sole and
absolute discretion, to file or not to file (A) a New Drug Application for Pirfenidone for an
indication of idiopathic pulmonary fibrosis with the FDA, or (B) a Marketing Authorization
Application for Pirfenidone for an indication of idiopathic pulmonary fibrosis with the EMEA. If
the Buyer decides to file a New Drug Application with the FDA and/or a Marketing Authorization
Application with the EMEA, then within ten (10) Business Days of such notification to the Sellers,
the Buyer shall deliver (or cause to be delivered) to the Sellers an aggregate amount of $[ * ] in
cash, payable by wire transfer in
immediately available funds in the allocations and to the accounts specified in Schedule
2.5 (the “Phase III Milestone Payment”).

          (ii) Upon the Buyer’s receipt of New Drug Application approval for Pirfenidone for an
indication of idiopathic pulmonary fibrosis in the United States, the Buyer shall deliver (or cause
to be delivered) to the Sellers an aggregate amount of $[ * ] in cash within fifteen (15) Business
Days, payable by wire transfer in immediately available funds in the allocations and to the
accounts specified in Schedule 2.5 (the “NDA Milestone Payment”); provided,
however, that the parties hereby acknowledge and agree that in the event the Buyer
determines, in good faith, that the labeling received by the Buyer from the FDA with respect to the
use of Pirfenidone for an indication of idiopathic pulmonary fibrosis materially and negatively
impacts the potential commercial value of Pirfenidone for idiopathic pulmonary fibrosis in the
United States, then the Sellers agree to, in good faith, (A) discuss with the Buyer the extent to
which labeling has negatively impacted the commercial value of Pirfenidone for idiopathic pulmonary
fibrosis in the United States and (B) negotiate an appropriate downward adjustment to the NDA
Milestone Payment to reflect such decrease in commercial value.

          (iii) Upon the Buyer’s receipt of Marketing Authorization Application approval for Pirfenidone
for an indication of idiopathic pulmonary fibrosis in Europe, the Buyer shall deliver (or cause to
be delivered) to the Sellers an aggregate amount of $[ * ] in cash within fifteen (15) Business
Days, payable by wire transfer in immediately available funds in the allocations and to the
accounts specified in Schedule 2.5 (the “MAA Milestone Payment”); provided,
however, that the parties hereby acknowledge and agree that in the event the Buyer
determines, in good faith, that the labeling received by the Buyer from the EMEA with respect to
the use of Pirfenidone for an indication of idiopathic pulmonary fibrosis materially and negatively
impacts the potential commercial value of Pirfenidone for idiopathic pulmonary fibrosis in Europe,
then the Sellers agree to, in good faith, (A) discuss with the Buyer the extent to which labeling
has negatively impacted the commercial value of Pirfenidone for idiopathic pulmonary fibrosis in
Europe and (B) negotiate an appropriate downward adjustment to the MAA Milestone Payment to reflect
such decrease in commercial value.

Each of the payments constituting the Purchase Price shall be deemed material, and any failure to
make any payment of any portion of the Purchase Price, if and when due, may be treated by the
Sellers as a material failure of consideration.

     Section 2.6 Risk of Loss. Until the Closing, any loss of or damage to the Purchased Assets from fire, flood, casualty or
any other similar occurrence shall be the sole responsibility of the Sellers. As of the Closing,
title to the Purchased Assets shall be transferred to the Buyer subject to the terms hereof. After
the Closing, the Buyer shall bear all risk of loss associated with the Purchased Assets and shall
be solely responsible for procuring adequate insurance to protect the Purchased Assets against any
such loss.

     Section 2.7 Allocation. As soon as practicable after the Closing, the Parties shall agree on an allocation (the
“Allocation”) of the Purchase Price (including any Assumed Liabilities to the extent
properly taken into account under the Code and the Treasury Regulations promulgated thereunder)
among the Purchased Assets and the Sellers’ covenants under Section 6.3 in accordance with
the requirements of Section 1060 of the Code and consistent with the principles set forth in
Schedule 2.7. The Parties agree to

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-11-

 

be bound by the Allocation, and the Parties shall act in accordance with the Allocation in the
preparation of financial statements and the filing of all Tax Returns (including, without
limitation, filing IRS Form 8594 with their Tax Returns for the taxable year that includes the
Closing Date), before any Tax authority or in any judicial proceeding unless it has the written
consent of the other Party to this Agreement or unless specifically required pursuant to a final
determination within the meaning of Section 1313(a) of the Code. No later than thirty (30) days
prior to the filing of their respective Forms 8594 (and analogous state law forms), each Party
shall deliver to the other Party a copy of such form. The Parties shall promptly advise each other
of the existence of any Tax proceeding related to the Allocation. In the event of an adjustment to
the Purchase Price pursuant to Section 6.5(c), the Buyer shall amend the Allocation to
reflect such adjustment, subject to approval by the Sellers, such approval not to be unreasonably
withheld. The Buyer and the Sellers agree to treat as interest for Tax purposes any portion of the
Purchase Price that is properly treated as interest under Section 483 of the Code (or any similar
provision applicable under state or local Law).

ARTICLE 3

CLOSING

     Section 3.1 Closing. Subject to the satisfaction or waiver of the conditions set forth in Sections 7.1 and
7.2, the closing of the transactions contemplated herein in connection with the purchase
and sale of the Purchased Assets (the “Closing”) shall be held at 10:00 a.m., local time,
on the second (2nd) Business Day following the satisfaction or waiver of all conditions
to the obligations of the Parties to consummate the transactions contemplated hereby (other than
conditions with respect to actions the respective Parties shall take at the Closing) at the offices
of Latham & Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, or such other time or place
as the Parties hereto shall otherwise agree (the “Closing Date”).

     Section 3.2 Closing Deliveries by the Sellers. At the Closing, the Sellers shall (i) take all steps necessary to place the Buyer in actual
possession and operating control of the Purchased Assets and (ii) deliver to the Buyer the
following items, duly executed by the Sellers as applicable, all of which shall be in form and
substance reasonably acceptable to the Buyer and in full force and effect:

     (a) Bill of Sale. Bill of Sale covering all of the applicable Purchased Assets,
substantially in the form of Exhibit A (the “Bill of Sale”);

     (b) Intellectual Property Assignment. Any and all documents necessary to properly
record the assignment to the Buyer of all of the Sellers’ right, title and interest in and to the
Product Intellectual Property, substantially in the form of Exhibit B (the “IP
Assignments”);

     (c) Consents. Duly executed Consents of all third parties (including any Governmental
Authorities), if any, required by the Sellers to consummate the transactions contemplated by this
Agreement and the Ancillary Agreements, in form and substance reasonably satisfactory to the Buyer,
including those Consents listed in Schedule 4.3(a);

     (d) Officer’s Certificates. A certificate executed on behalf of each of the Sellers
by an executive officer of KDL GmbH, and individually by Dr. Yamauchi, dated as of the Closing
Date, certifying that the conditions set forth in Section 7.1(a), Section 7.1(b)
and Section 7.1(d) have been satisfied in all respects (the “Officer’s
Certificate”);

     (e) Secretary’s Certificate. A certificate of the Secretary of KDL GmbH certifying as
to:

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-12-

 

          (i) The certificate of incorporation and bylaws (or comparable organizational documents) of
KDL GmbH as in effect as of the Closing Date;

          (ii) resolutions of KDL GmbH’s board of directors authorizing the execution, delivery and
performance of this Agreement and the Ancillary Agreements; and

          (iii) the incumbency of KDL GmbH’s officers executing this Agreement and the Ancillary
Agreements; and

     (f) Certificate of Good Standing. Certificates from appropriate Governmental
Authorities from Switzerland as to KDL GmbH’s existence and good standing under Swiss law and, if
applicable, payment of all applicable taxes, dated no earlier than three (3) Business Days prior to
the Closing Date.

     Section 3.3 Closing Deliveries and Payments by the Buyer . The Buyer shall pay the Closing Payment.

     Section 3.4 Closing Deliveries by the Buyer and the Sellers. At the Closing, the Buyer and the Sellers shall deliver the following items to one another, duly
executed and in full force and effect:

     (a) Assignment and Assumption Agreement. Assignment and Assumption Agreement,
covering all of the Assumed Liabilities, substantially in the form of Exhibit C (the
“Assignment and Assumption Agreement”).

     (b) Other Documentation. Such other certificates, instruments or documents required
pursuant to the provisions of this Agreement or otherwise necessary or appropriate to transfer the
Purchased Assets and Assumed Liabilities in accordance with the terms hereof and consummate the
transactions contemplated by this Agreement and the Ancillary Agreements, and to vest in the Buyer
full and complete title to the Purchased Assets free and clear of any Encumbrances, except for
Permitted Encumbrances.

     Section 3.5 Liabilities Related to Finders’ or Brokers’ Fees. For the avoidance of doubt, the Parties agree that (i) all Liabilities in respect of finder’s
fees, brokerage fees or commissions or similar payments arising out of or relating to the Purchased
Assets in connection with any Seller’s entry into this Agreement or the consummation of any of the
transactions contemplated hereby shall remain Excluded Liabilities pursuant to Section 2.4, and
(ii) the Buyer shall reserve all rights pursuant to Article 8 (including Section 8.2(a)(iii)).

     Section 3.6 Further Actions. From and after the Closing, each Seller shall cooperate with the Buyer and the Buyer’s
Affiliates and Representatives, and shall execute and deliver such documents and take such other
actions as the Buyer may reasonably request, for the purpose of evidencing the transactions
contemplated by this Agreement or the Ancillary Agreements and putting the Buyer in possession and
control of all of the Purchased
Assets, including using their reasonable best efforts to obtain all necessary Consents from other
parties to the Assumed Contracts. Each of the Sellers hereby irrevocably nominates, constitutes
and appoints the Buyer as the true and lawful attorney-in-fact of each of the Sellers (with full
power of substitution) effective as of the Closing Date, limited to the purposes contemplated by
this Agreement and the Ancillary Agreements, and hereby authorizes the Buyer (in the name of and on
behalf of each of the Sellers) to execute, deliver, acknowledge, certify, file and record any
document, to institute and prosecute any Action and to take any other action (on or at any time
after the Closing Date) that the Buyer may deem reasonably appropriate for the purpose of (a)
collecting, asserting, enforcing or perfecting any claim, right or interest of any kind that is
included in or relates to any of the Purchased Assets, (b) defending or compromising any claim or
Action relating to any of the Purchased

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-13-

 

Assets (subject to the provisions of Section 8.2 in the case of a Claim for
indemnification) or (c) otherwise carrying out or facilitating any of the transactions contemplated
by this Agreement or the Ancillary Agreements. The power of attorney referred to in the preceding
sentence is and shall be coupled with an interest and shall be irrevocable, and shall survive the
dissolution or insolvency of KDL GmbH.

     Section 3.7 Withholdings. The Buyer shall be entitled to deduct and withhold from any consideration payable or otherwise
deliverable pursuant to this Agreement such amounts as may be required to be deducted or withheld
therefrom under any provision of federal, local or foreign Tax law or under any applicable Law. To
the extent such amounts are so deducted or withheld, such amounts shall be treated for all purposes
under this Agreement as having been paid to the Person to whom such amounts would otherwise have
been paid.

ARTICLE 4

REPRESENTATIONS AND WARRANTIES OF THE SELLERS

     Each Seller represents and warrants, jointly and severally, to the Buyer that the statements
contained in this Article 4 are true and correct as of the date of this Agreement and will be true
and correct as of the Closing Date as if made on such date, except as set forth in the disclosure
schedules delivered by the Sellers to the Buyer on the date of this Agreement (collectively, such
schedules being referred to herein as the “Sellers Disclosure Schedule”). The Sellers
Disclosure Schedule shall be arranged in paragraphs corresponding to the numbered sections
contained in this Article 4 and the disclosure in any paragraph shall qualify other sections in
this Article 4 only to the extent that it is readily apparent from a reading of such disclosure
that it also qualifies or applies to such other sections.

     Section 4.1 Organization and Authority. KDL GmbH is a corporation duly organized, validly existing and in good standing under the laws
of Switzerland. Each Seller has all requisite power and authority to execute and deliver this
Agreement and the Ancillary Agreements, to perform its respective obligations hereunder and
thereunder and to consummate the transactions contemplated hereby and thereby and, in the case of
KDL GmbH, has duly authorized the execution, delivery and performance of this Agreement and the
Ancillary Agreements and transactions or documents contemplated hereby and thereby by all necessary
corporate action. The Sellers have all requisite power and authority necessary to own, lease and
operate their respective assets, to carry on the Product Business to the extent currently being
conducted by them, and to perform their respective obligations under all Contracts. This Agreement
and the Ancillary Agreements, when
executed and delivered by the Sellers, constitute the valid and legally binding obligations of the
Sellers, enforceable against each of them in accordance with their respective terms, subject to
applicable bankruptcy, moratorium, reorganization, insolvency and similar laws of general
application relating to or affecting the rights and remedies of creditors generally and to general
equitable principles (regardless of whether in equity or at law).

     Section 4.2 Title to Purchased Assets. The Sellers have good and marketable title to the Purchased Assets free and clear of any
Encumbrances, except for Permitted Encumbrances. Upon the consummation of the transactions
contemplated hereby, the Buyer will acquire good and marketable title to the Purchased Assets free
and clear of any Encumbrances, except for Permitted Encumbrances. None of the Sellers has received
any notice of any adverse claims of ownership to or right to use the Purchased Assets, and to the
Sellers’ Knowledge, no facts or circumstances exist which would provide a reasonable basis for any
such adverse claim of ownership or right to use any of the Purchased Assets.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-14-

 

     Section 4.3 Consents; No Violations.

     (a) Except for all filings and other actions contemplated by this Agreement and the Ancillary
Agreements (including the necessary transfer of filings, notices and approvals required to transfer
the Regulatory Approvals from the Sellers to the Buyer), the execution, delivery and performance by
the Sellers of this Agreement and the Ancillary Agreements and the consummation by the Sellers of
the transactions contemplated hereby and thereby will not require any notice to, filing with, or
the consent, approval or authorization of, any Person or Governmental Authority
(“Consents”).

     (b) Neither the execution and delivery of this Agreement or the Ancillary Agreements nor the
consummation of the transactions contemplated hereby or thereby will (i) violate or result in a
breach or result in the acceleration or termination of, or the creation in any third party of the
right to accelerate, terminate, modify or cancel, any Contract primarily related to the Purchased
Assets and/or the Assumed Liabilities, (ii) conflict with, violate or result in a breach of any
provision of the certificate of incorporation or by-laws (or comparable organizational documents)
of KDL GmbH, or (iii) conflict with or violate in any material respect any applicable Law.

     Section 4.4 Compliance with Laws and Litigation .

     (a) With respect to the Product Business, the Purchased Assets and the Assumed Liabilities, to
the Knowledge of the Sellers, the Sellers are in material compliance with all applicable Laws.

     (b) There is no existing or pending or, to the Knowledge of the Sellers, threatened Action
with respect to the Product Business, the Purchased Assets or the Assumed Liabilities or with
respect to this Agreement or the transactions contemplated hereby. None of the Sellers is subject
to any Order of any Governmental Authority that would reasonably be expected to impair or delay its
ability to perform its obligations under, and consummate the transactions contemplated, by this
Agreement.

     Section 4.5 Contracts. 

     (a) The Sellers have delivered to or made available to the Buyer accurate and complete copies
of all Contracts primarily related to the Purchased Assets and/or the Assumed Liabilities. All
such
Contracts to which any Seller is a party are, as to such Seller (and, as to the other parties
thereto, to the Knowledge of the Sellers), legal, valid and binding agreements in full force and
effect and enforceable in accordance with its terms (subject to applicable bankruptcy, moratorium,
reorganization, insolvency and similar laws of general application relating to or affecting the
rights and remedies of creditors generally and to general equitable principles (regardless of
whether in equity or at law)).

     (b) None of the Sellers is in breach or default, and no event has occurred that with notice or
lapse of time would constitute a breach or default by any Seller permitting termination,
modification, or acceleration, under any Contract primarily related to the Purchased Assets and/or
Assumed Liabilities. To the Knowledge of the Sellers, no other party to any Contract is in
material breach or default under, or has repudiated any material provision of, any Contract
primarily related to the Purchased Assets and/or Assumed Liabilities.

     Section 4.6 Tax Matters. Each Seller has timely filed all Tax Returns required to be filed, and has paid all Taxes due,
with respect to the Purchased Assets and the Product Business. There are no Encumbrances on any of
the Purchased Assets for Taxes (except for current Taxes not yet due and payable). There are no
asserted, and the Sellers have no Knowledge of any basis for the assertion of any, claims relating
to Taxes which, if adversely determined, could reasonably be expected to result in any such
Encumbrance.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-15-

 

     Section 4.7 Intellectual Property. 

     (a) Section 4.7(a) of the Sellers Disclosure Schedule set forth a true and complete
list of the Product Patents and the Product Trademarks.

     (b) To the Knowledge of the Sellers, (i) the activities of the Sellers, if any, relating to
the development, manufacture, marketing, use, sale, distribution, import, export or other
commercial exploitation of Pirfenidone by the Sellers, in each case do not infringe upon,
misappropriate, violate, dilute (with respect to any trademarks, trade names, brand names and
service marks) or otherwise constitute the unauthorized use of, the Intellectual Property rights of
any third party; (ii) no claim is pending or, to the Knowledge of the Sellers, threatened against
the Sellers alleging any of the foregoing; and (iii) to the Knowledge of the Sellers, no right,
license, lease, consent or other agreement is required with respect to any Product Intellectual
Property for the conduct of the Product Business other than those included in the Purchased Assets.

     (c) To the Knowledge of the Sellers, none of the Product Patents is involved in any
litigation, reissue, interference, reexamination, or opposition, and there has been no threat or
other indication that any such proceeding will hereafter be commenced. To the Knowledge of the
Sellers, the Product Patents (excluding patent applications) (i) are in good standing, (ii) are all
without challenge of any kind, (iii) are valid and enforceable, and (iv) have not been adjudged
invalid or unenforceable in whole or in part.

     (d) To the Knowledge of the Sellers, none of the Product Trademarks or Product Copyrights is
involved in any cancellation, nullification, interference, conflict, concurrent use or opposition
proceeding, and there has been no threat or other indication that any such proceeding will
hereafter be commenced.

     (e) No Actions are pending, or to the Knowledge of the Sellers are threatened, against any of
the Sellers (i) based upon challenging or seeking to deny or restrict the use of any of the Product
Intellectual Property, or (ii) alleging that any services provided by, processes used by, or
products manufactured or sold by the Sellers in relation to the Product Business infringe or
misappropriate any Intellectual Property right of any third party.

     (f) To the Knowledge of the Sellers, all maintenance fees, annuity fees or renewal fee payment
for each jurisdiction in which each patent, patent application, trademark, trademark application,
trade name, trade name registration, brand name, brand name registration, service mark, service
mark registration, copyright, copyright application, domain name or domain name application
included within the Product Intellectual Property has issued or is pending have been timely paid.

     (g) To the Knowledge of the Sellers, no third party is engaging in any activity that infringes
or misappropriates the Product Intellectual Property. None of the Sellers is a party to any
agreement granting rights by the Sellers to any third party with respect to the Product
Intellectual Property.

     (h) The Sellers have, with respect to the Product Business, used commercially reasonable
efforts to maintain their trade secrets in confidence.

     (i) To the Knowledge of the Sellers, there has been no misappropriation of any trade secrets
or other confidential information of the Sellers with respect to the Product Business.

     (j) All employees of, consultants to or vendors of the Sellers with access to confidential
information with respect to the Product Business are parties to written agreements under which each
such employee, consultant or vendor is obligated to maintain the confidentiality of confidential
information of the Sellers. To the Knowledge of the Sellers, none of the employees, consultants or
vendors of the Sellers or any of their subsidiaries is in violation of such agreements.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-16-

 

     (k) The execution, delivery and performance of this Agreement, and the consummation of the
transactions contemplated hereby, will not result in or give rise to any right of termination or
other right to impair or limit, or otherwise result in a breach of, any of the Sellers’ rights to
own or retain a license to any of the Product Intellectual Property.

     (l) To the Knowledge of the Sellers, the Sellers have disclosed to the Buyer all patentable
Product Know-How.

     Section 4.8 Product Records. To the Knowledge of the Sellers, all of the Product Records have been made available by the
Sellers to the Buyer for examination, are complete and correct in all material respects, and have
been maintained in accordance with sound business practices and applicable Law.

     Section 4.9 Brokers, Finders, etc. Except as set forth in Section 4.9 of the Sellers Disclosure Schedule, none of the
Sellers nor any of their respective officers, directors, employees, stockholders or Affiliates has
employed or made any agreement with any broker, finder or similar agent or any Person which will
result in the obligation of the Buyer or
any of its Affiliates to pay any finder’s fee, brokerage fees or commission or similar payment in
connection with the transactions contemplated hereby.

     Section 4.10 No Other Agreements to Sell the Purchased Assets. None of the Sellers nor any of KDL GmbH’s officers, directors, stockholders or Affiliates has
any commitment or legal obligation, absolute or contingent, to any other Person other than the
Buyer to sell, assign, transfer or effect a sale of any of the Purchased Assets, to sell or effect
a sale of a majority of the capital stock of KDL GmbH, to effect any merger, consolidation,
liquidation, dissolution or other reorganization of KDL GmbH, or to enter into any agreement or
cause the entering into of an agreement with respect to any of the foregoing.

     Section 4.11 Disclosure. This Agreement, the Sellers Disclosure Schedule and the Ancillary Agreements do not contain any
untrue statement of a material fact or, to the Knowledge of the Sellers, omit to state a material
fact necessary in order to make the statements contained herein or therein not misleading. The
Sellers have provided the Buyer with all information requested by the Buyer in connection with this
transaction and all information that the Sellers considers necessary or appropriate to enable the
Buyer to decide whether to purchase the Purchased Assets and assume the Assumed Liabilities. To
the Sellers’ Knowledge, there are no facts which (individually or in the aggregate) materially
affect the Purchased Assets and/or the Assumed Liabilities that have not been set forth in the
Agreement, the Sellers Disclosure Schedule and the Ancillary Agreements.

     Section 4.12 Disclaimer of Implied Warranty. EACH OF THE SELLERS HEREBY DISCLAIMS ANY IMPLIED WARRANTY AS TO THE LEGAL EFFECT OF THE
PURCHASED ASSETS, THE FITNESS OF THE PURCHASED ASSETS FOR THEIR INTENDED PURPOSE, THE
MERCHANTABILITY OF THE PURCHASED ASSETS, AND ALL OTHER WARRANTIES WHICH MAY BE IMPLIED AT LAW. THE
PURCHASED ASSETS ARE SOLD “AS IS”, WITHOUT WARRANTY OTHER THAN WARRANTIES OF TITLE AND WARRANTIES
EXPRESSLY SET OUT IN THIS AGREEMENT. This disclaimer of warranty, however, shall not disclaim the
implied contractual covenant of good faith and fair dealing, which the Sellers hereby expressly
recognize as applicable to this Agreement; and any warranty which may not be disclaimed as a matter
of patent or any other Law. The Buyer acknowledges that it is not relying upon any statement,
representation or warranty not expressly contained in this Agreement or in the Seller Disclosure
Schedule. Notwithstanding the foregoing, each Seller hereby acknowledges that nothing set forth in
this Section 4.12 shall relieve the Sellers of any liability to the Buyer arising out of
any actual fraud or intentional

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-17-

 

misrepresentation of the Sellers or any of their respective Representatives in connection with the
transactions contemplated by this Agreement.

     The Sellers make no representation or warranty that the Product Patents may not be invalidated
in the future by any Governmental Authority, although to the Knowledge of the Sellers, there is no
Action currently contemplated, threatened or underway that may result in the invalidation of any of
the Product Patents.

     Section 4.13 Regulatory Matters.

     (a) None of the Sellers has any existing, pending or withdrawn Regulatory Approvals, including
Product Registrations. The Sellers do not require any Regulatory Approvals to carry on the Product
Business as being conducted by the Sellers as of the Closing Date and which are required by
applicable Law.

     (b) None of the Sellers, nor any third party on behalf of any Seller, has conducted or is
currently conducting any preclinical or clinical trials relating to Pirfenidone. None of the
Sellers has submitted any materials or made any applications to the FDA, the EMEA or other
comparable Governmental Authorities.

     (c) None of the Sellers, nor any third party on behalf of any Seller, has developed, labeled,
stored, tested, manufactured or distributed any Pirfenidone or Product.

     (d) None of the Sellers has received any notice from any Governmental Authority that such
Governmental Authority has commenced, threatened or intends to commence any action or investigation
with respect to the Product Business, and there are no facts, circumstances or conditions that
would be sufficient to presently, or solely with the passage of time in the ordinary course of
business, provide a reasonable basis for any such action or investigation.

ARTICLE 5

REPRESENTATIONS AND WARRANTIES OF BUYER

     The Buyer represents and warrants to the Sellers that the statements contained in this Article
5 are true and correct as of the date of this Agreement and will be true and correct as of the
Closing Date as if made on such date, except as set forth in the disclosure schedules delivered by
the Buyer to the Sellers on the date of this Agreement (the “Buyer Disclosure Schedule”).
The Buyer Disclosure Schedule shall be arranged in paragraphs corresponding to the numbered
sections contained in this Article 5 and the disclosure in any paragraph shall qualify other
sections in this Article 5 only to the extent that it is readily apparent from a reading of such
disclosure that it also qualifies or applies to such other sections.

     Section 5.1 Organization and Authority. The Buyer is a corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware. The Buyer has all requisite power and authority to execute and deliver
this Agreement and the Ancillary Agreements, to perform its respective obligations hereunder and
thereunder and to consummate the transactions contemplated hereby and thereby, and has duly
authorized the execution, delivery and performance of this Agreement and the Ancillary Agreements
and transactions or documents contemplated hereby and thereby by all necessary corporate action.
This Agreement and the Ancillary Agreements, when executed and delivered by the Buyer, constitute
the valid and legally binding obligations of the Buyer, enforceable against it in

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-18-

 

accordance with their respective terms, subject to applicable bankruptcy, moratorium,
reorganization, insolvency and similar laws of general application relating to or affecting the
rights and remedies of creditors generally and to general equitable principles (regardless of
whether in equity or at law).

     Section 5.2 Consents; No Violations.

     (a) Except for all filings and other actions contemplated by this Agreement and the Ancillary
Agreements (including the necessary transfer of filings, notices and approvals required to transfer
the Regulatory Approvals from the Sellers to the Buyer), the execution, delivery and performance by
the Buyer of this Agreement and the Ancillary Agreements and the consummation by the Buyer of the
transactions contemplated hereby and thereby will not require any notice to, filing with, or the
consent, approval or authorization of, any Person or Governmental Authority.

     (b) Neither the execution and delivery of this Agreement or the Ancillary Agreements nor the
consummation of the transactions contemplated hereby or thereby will (i) violate or result in a
breach or result in the acceleration or termination of, or the creation in any third party of the
right to accelerate, terminate, modify or cancel, any indenture, contract, lease, sublease, loan
agreement, note or other obligation or liability to which the Buyer is a party or is bound, (ii)
conflict with, violate or result in a breach of any provision of the certificate of incorporation
or by-laws of the Buyer, or (iii) conflict with or violate in any material respect any applicable
Law.

     Section 5.3 Brokers, Finders, etc. Neither the Buyer nor any of its officers, directors, employees, stockholders or Affiliates has
employed or made any agreement with any broker, finder or similar agent or any person or firm which
will result in the obligation of the Buyer or any of its Affiliates to pay any finder’s fee,
brokerage fees or commission or similar payment in connection with the transactions contemplated
hereby.

ARTICLE 6

CERTAIN OTHER COVENANTS

     Section 6.1 Cooperation.

     (a) After the Closing Date, the Parties shall cooperate reasonably with each other in
connection with any reasonable actions required to be taken with respect to their respective
obligations under this Agreement and the Ancillary Agreements, and shall (i) furnish upon
reasonable request to each other such further information, (ii) execute and deliver to each other
such other reasonable documents, and (iii) do such other acts, all as the other Party may
reasonably request for the purpose of carrying out the provisions of this Agreement (and the
Ancillary Agreements) and the transactions contemplated hereby and thereby.

     (b) The Sellers will promptly notify the Buyer, and the Buyer will notify the Sellers, as
applicable and in writing, of any event or fact which represents a material breach of any of their
respective representations, warranties, covenants or agreements hereunder.

     (c) Within ninety (90) days of the Closing Date, the Sellers shall deliver (or cause to be
delivered) to the Buyer any Purchased Assets not required to be delivered at Closing pursuant to
Section 3.2.

     (d) From the Closing Date through the first anniversary of the Closing Date, upon the Buyer’s
request, each Seller shall: (i) reasonably assist the Buyer in the maintenance and renewal of any
Regulatory Approvals and the performance of any compliance activities under applicable Law, (ii)

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-19-

 

reasonably assist the Buyer in the preparation of any maintenance or renewal filings with respect
to any Product Intellectual Property, and (iii) provide such other cooperation and assistance as
reasonably requested by the Buyer.

     (e) At least thirty (30) days prior to the submission for publication, including public
presentation, of any Copyrights primarily related to Pirfenidone, including any scientific papers
and academic materials by Dr. Yamauchi or other KDL GmbH employees, the Sellers shall provide
complete copies of all such materials to the Buyer for the Buyer’s review. If the materials
provided to the Buyer are in draft form or are later revised prior to publication, the Sellers
shall continue to provide revised copies of all such materials until a complete and final copy has
been provided to the Buyer for the Buyer’s review. The Buyer will, in all such cases, have at
least thirty (30) days to review and comment on the materials prior to publication. The Sellers
shall reasonably consider for inclusion in such publication the comments of the Buyer. Should the
Buyer desire to file a patent application on any inventions within such proposed publication, the
Buyer shall so notify the Sellers prior to the expiration of the thirty (30) day review period and
the Sellers shall, upon receipt of such notice, delay publication for up to an additional thirty
(30) days and cooperate with the Buyer in the preparation of such patent application. The Buyer
shall own all rights, title and interest in all such patent applications and patents claiming
inventions disclosed in all such publications and materials. The Sellers hereby assign all rights
to any and all such patent applications and patents to the Buyer. The Sellers shall cooperate with
the Buyer to perfect any such assignments, including executing, or causing to be executed, any
formal papers necessary.

     Section 6.2 Billing and Invoices. In the event that any Seller or any of their respective Affiliates receive payment after the
Closing Date on invoices relating to any business arising from the Purchased Assets operated by the
Buyer or sales of products or services rendered by the Buyer on or after the Closing Date, such
Seller will promptly notify the Buyer of such receipt and will promptly remit, or will cause such
Affiliate to promptly remit, such payment to the Buyer without depositing such payment in an
account of such Seller, or such Affiliate, unless in error, and such Seller, or such Affiliate,
shall not be entitled to offset such payment against any payments due such Sellers from the Buyer.
In the event that any Seller receives an invoice or request for payment relating to the operation
of any business arising from the Purchased Assets on or after the Closing Date, or with respect to
any Assumed Liability, such Seller will promptly notify the Buyer of such request or invoice and
forward the invoice and all other appropriate information to the Buyer for payment. In the event
the Buyer or any of its Affiliates receive payment after the Closing Date on invoices issued by any
Sellers relating to an Excluded Asset or relating to product sold or services rendered by
businesses other than those relating to the Purchased Assets, the Buyer will promptly notify the
Sellers of such receipt and will promptly remit, or will cause such Affiliate to promptly remit,
such payment to the Sellers without depositing such payment in an account of the Buyer, or such
Affiliate, unless in error, and the Buyer, or such Affiliate, shall not be entitled to offset such
payment against any payments due the Buyer from the Sellers.

     Section 6.3 Covenant Not To Compete.

     (a) Each Seller hereby agrees that for a period of ten (10) years from and after the Closing
Date, such Seller shall not, directly or indirectly, alone, as a licensor, or otherwise in
conjunction with any other Persons, through licenses or otherwise, develop, manufacture,
license-in, market, sell or otherwise distribute for human use, or assist any other Person, in
developing, manufacturing, licensing-in, marketing, selling or otherwise distributing for human
use, any Competing Product, either alone or in combination with another product, in all or any
portion of the Restricted Territory.

     (b) Acknowledgment of the Sellers. Each Seller hereby acknowledges that (i) the value
of the Purchased Assets is an integral component of the value of the transactions contemplated by
this

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-20-

 

Agreement to the Buyer, and (ii) the scope of the covenants contained in this Section 6.3,
including as to time and geography, are necessary to preserve the value of the Purchased Assets for
the Buyer. Each Seller also acknowledges that the limitations of time, geography and scope of
activity agreed to in this Section 6.3 are ongoing executory duties of each Seller and are
reasonable because, among other things, (i) the Buyer and the Sellers are engaged in a highly
competitive industry, (ii) the Sellers have had unique access to the trade secrets and know-how of
the Purchased Assets, including the plans and strategy (and, in particular, the competitive
strategy) relating to the Purchased Assets, and (iii) the Sellers are receiving significant
consideration in connection with the consummation of the transactions contemplated by this
Agreement.

     (c) Non-Competition Covenants; Scope.

          (i) If any agreement in this Section 6.3 or any part of such agreement is held
invalid, void or unenforceable by any court of competent jurisdiction, such invalidity, voidness,
or unenforceability shall in no way render invalid, void, or unenforceable any other part of such
agreement or any separate agreement not declared invalid, void or unenforceable, and this
Section 6.3 shall in such case be construed as if the invalid, void, or unenforceable
provisions were omitted.

          (ii) If any court of competent jurisdiction shall determine that the provisions of this
Section 6.3 exceed the time, geographic or scope limitations permitted by applicable Law,
then such provisions shall nevertheless be enforceable by such court against any Seller upon such
shorter term, or within such lesser geographic area or scope, as may be determined by such court to
be reasonable and enforceable.

     (d) Injunctive Relief. The Parties agree that in the event of a breach by a Seller of
any of the covenants set forth in this Section 6.3, monetary damages alone would be
inadequate to fully protect the Buyer from, and compensate the Buyer for, the harm caused by such
breach or threatened breach. Accordingly, each Seller agrees that if it breaches or threatens
breach of any provision of this Section 6.4, the Buyer shall be entitled to, in addition to
any other right or remedy otherwise available, injunctive relief restraining such breach or
threatened breach and to specific performance of any such provision of this Section 6.3.
The Buyer shall not be required to post a bond or other security in connection with, or as a
condition to, obtaining such relief before a court of competent jurisdiction.

     Section 6.4 Exclusive License; Right of First Refusal.

     (a) The Buyer hereby grants an irrevocable, fully paid-up, royalty-free, perpetual,
transferable, sublicensable, exclusive license to the Product Patents to the Seller or Sellers who
owned such Product Patent immediately prior to the consummation of the transactions contemplated by
this Agreement (the “Patent Transferor”) solely to the extent that such Product Patents [ *
] and solely to the extent necessary to [ * ]. The Buyer shall execute such documents to evidence
such transfers as may be reasonably requested by the Sellers, including documents for filing with
the United States Patent and Trademark Office and other relevant patent agencies.

     (b) The Buyer shall have the right to terminate the license granted pursuant to Section
6.4(a) of this Agreement effective immediately upon written notice if any Patent Transferor or
any of their respective Affiliates, or any sublicensee under any patent right licensed to such
Patent Transferor under Section 6.4(a) of this Agreement or any of their respective
Affiliates challenges in a court of competent jurisdiction, the validity, scope or enforceability
of, or otherwise opposes, any patent right covered by the Product Patents, including any patent
right licensed to any Patent Transferor under Section 6.4(a) of this Agreement. If a
sublicensee under any patent right licensed to such Patent Transferor under Section 6.4 (a)
of this Agreement or any of their respective Affiliates challenges the validity, scope or
enforceability

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-21-

 

of or otherwise opposes any patent right covered by the Product Patents, including any patent right
licensed to any Patent Transferor under Section 6.4(a) of this Agreement under which such
sublicensee is sublicensed, then such Patent Transferor or its respective Affiliate, as applicable,
shall, upon written notice from the Buyer, terminate such sublicense. Each Patent Transferor and
its respective Affiliates shall include provisions in all agreements under which a third party
obtains a license under any patent right licensed to such Patent Transferor under Section
6.4(a) of this Agreement providing that, if the sublicensee challenges the validity or
enforceability of or otherwise opposes any such patent right under which the sublicensee is
sublicensed, then such Patent Transferor may terminate such sublicense agreement with such
sublicensee, and such Patent Transferor shall, upon request by the Buyer, enforce such right if
such sublicensee breaches such restriction.

     (c) Each Patent Transferor agrees that for a period of six (6) years from the date of this
Agreement, such Patent Transferor shall not, directly or indirectly (including through any of its
Affiliates), at any time prior to the approval by the FDA of an IND or by the EMEA of a Clinical
Trial Authorization with respect to such [ * ], enter into any agreement, understanding or
arrangement (or discussions or negotiations therefor) with any Person that effects or contemplates
the licensing, sale or transfer of any rights in or to assets relating to such [ * ]. Upon the FDA
approval of an IND or the EMEA approval of a Clinical Trial Authorization with respect to such [ *
] at any time within the six (6) year period referenced in the foregoing sentence, such Patent
Transferor(s) shall promptly provide the Buyer with (i) a copy of such FDA or EMEA approval and
(ii) all the available and relevant data from the studies (collectively, the “Approval Notice
and Report”). The Buyer shall have the right to conduct due diligence for a period of up to
sixty (60) days from the date that Buyer receives the Approval Notice and Report from the Patent
Transferor(s) (such period, the “Diligence Period”). The Buyer’s due diligence during the
Diligence Period may include the following: (A) a full pre-clinical or clinical (as applicable) and
manufacturing audit of the Patent Transferor(s), (B) the right to reasonably request all relevant
data, including raw data, obtained to date, and (C) the right to inspect the Patent Transferor(s)
facilities and, to the extent within the reasonable control of the Patent Transferor(s), the
facilities of its clinicians and manufacturers (and the Patent Transferor(s) agree to use their
commercially reasonable efforts to ensure that the Buyer may inspect the facilities of such third
parties).

     (d) The Buyer shall have the right of first refusal (in its sole and absolute discretion) to
enter into negotiations with such Patent Transferor(s) for further research, development and
commercialization of an [ * ] in connection with an Approval Notice and Report (the “Right of
First Refusal”). The Buyer’s Right of First Refusal shall expire upon the expiration of the
underlying Diligence Period unless the Buyer exercises its Right of First Refusal by delivering
written notice to the Patent Transferor(s) (a “ROFR Notice”) prior to such expiration, in
which case the Parties shall negotiate in good faith to enter into a definitive agreement with
respect to the research, development and/or commercialization of such [ * ] within 90 days of the
Patent Transferor(s) receipt of such ROFR Notice. Each Patent Transferor further agrees to not,
directly or indirectly (including through any of its Affiliates), enter into any agreement,
understanding or arrangement (or discussions or negotiations therefor) with any Person (other than
the Buyer) that effects or contemplates the licensing, sale or transfer of any rights in or to
assets relating to such [ * ] unless and until the Buyer’s Right of First Refusal has expired in
accordance with this Section 6.4(d).

     Section 6.5 Tax Matters.

     (a) Notices. The Sellers shall promptly notify the Buyer in writing upon receipt by
the Sellers of notice of any pending or threatened Tax audits or assessments relating to the
income, properties or operations of the Sellers that reasonably may be expected to relate to the
Purchased Assets, the Assumed Liabilities or the Product Business. The Buyer shall promptly notify
the Sellers in writing upon

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-22-

 

receipt by the Buyer of notice of any pending or threatened Tax audits or assessments relating to
the Product Patents as to which the Sellers have an interest pursuant to Section 6.4(a) or
Section 6.7.

     (b) Transfer Taxes. All Transfer Taxes shall be paid by the Sellers when due, and the
Sellers shall, at their own expense, file all necessary Tax Returns and other documentation with
respect to all such Transfer Taxes and, if required by applicable Law, the Buyer shall join in the
execution of any such Tax Returns and other documentation. As soon as reasonably practicable
following the Closing, the Sellers shall provide the Buyer with (i) evidence satisfactory to the
Buyer that such Transfer Taxes have been paid by the Sellers and (ii) a clearance certificate or
similar document(s) which may be required by any state Tax authority to relieve the Buyer of any
obligation to withhold any portion of the payments to the Sellers pursuant to this Agreement.

     (c) Characterization of Payments. Except as otherwise provided in this Agreement, any
payments made pursuant to any indemnification obligation under this Agreement shall constitute an
adjustment of the consideration paid for the Purchased Assets for Tax purposes and shall be treated
as such by the Buyer and the Sellers on their Tax Returns to the extent permitted by Law.

     (d) FIRPTA Certificate. The Sellers shall deliver to the Buyer at the Closing a
certificate, duly executed and acknowledged, in form and substance satisfactory to the Buyer,
certifying such facts as would exempt the transactions contemplated hereby from withholding
pursuant to the provisions of the Foreign Investment in Real Property Tax Act.

     (e) Allocation of Taxes.

          (i) Except as otherwise provided in this Section 6.5, the Sellers shall be responsible
for, and shall timely pay, all Taxes levied with respect to the Purchased Assets and the Product
Business attributable to the Pre-Closing Tax Period.

          (ii) Non-Income Taxes for any Straddle Period shall be apportioned between the Pre-Closing Tax
Period and the Post-Closing Tax Period as follows: (A) in the case of personal property Taxes, real
property Taxes and any other Taxes other than sales, use, transaction or excise Taxes and other
similar Taxes, the portion allocable to the Pre-Closing Tax Period shall be deemed to be the amount
of such Tax for the entire Straddle Period multiplied by a fraction the numerator of which is the
number of days in the portion of the Straddle Period ending on the Closing Date and the denominator
of which is the number of days in the entire Straddle Period, and (B) in the case of any sales,
use, transaction or excise Taxes or other similar Taxes, the portion allocable to the Pre-Closing
Tax Period shall be deemed equal to the amount which would be payable if the relevant Straddle
Period ended on the Closing Date. The Sellers shall be liable for Non-Income Taxes apportioned to
the Pre-Closing Tax Period, and the Buyer shall be liable for Non-Income Taxes apportioned to the
Post-Closing Tax Period.

          (iii) Upon receipt by the Buyer, on the one hand, or a Seller, on the other, of any bill for
Taxes relating to the Purchased Assets or the Product Business, the Party receiving such bill (the
“Recipient Party”) promptly shall present a statement to the other Party (the “Other
Party”) setting forth the amount of such Taxes for which the Other Party is liable under this
Section 6.5(e), together with such supporting evidence as is reasonably necessary to
calculate the amount of such Taxes. The apportioned amount of Taxes for which the Other Party is
liable shall be paid by the Other Party to the Recipient Party within 15 days after delivery of
such statement to the Other Party by the Recipient Party. The Recipient Party shall be responsible
for the timely payment of the Taxes to which such bill relates. In the event that a Party shall
make any payment to any Taxing or other authority of any Taxes apportioned to the Other Party under
Section 6.5(e), the Other Party shall reimburse the paying Party for the amount of such
Taxes apportioned to the Other Party promptly but in no event later than 15 days after the
presentation by the

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-23-

 

paying Party of a statement setting forth the amount of reimbursement to which the paying Party is
entitled along with such supporting evidence as is reasonably necessary to calculate the amount of
such reimbursement. The portion of any refund of Taxes attributable to amounts apportioned
hereunder to and paid or reimbursed by the Party not receiving such refund shall be the property of
the Party not receiving such refund, and the Party receiving such refund shall promptly pay to the
Party not receiving such refund that portion of such refund so attributable.

     (f) Cooperation. The Buyer and the Sellers agree to furnish or cause to be furnished
to the other, upon request, as promptly as practicable, such information and assistance relating to
the Purchased Assets or the Product Business as is reasonably necessary for the filing of Tax
Returns and the prosecution or defense of any audit, claim, suit or proceeding relating to any Tax.
The Parties shall retain all books and records with respect to Taxes pertaining to the Purchased
Assets for a period of at least seven (7) years following the Closing Date. At the end of such
period, the Parties shall provide the other Party with reasonable prior written notice before
disposing of such books and records and to allow the other Party to take possession, at its own
expense, of such books and records. The Parties shall cooperate fully with each other in the
conduct of any audit or other proceeding relating to Taxes pertaining to the Purchased Assets and
further agree to use their best efforts to obtain any certificate or other document from any
Governmental Authority or other Person as may be necessary to mitigate, reduce or eliminate any Tax
that could be imposed (including with respect to the transactions contemplated hereby).

     Section 6.6 Notice to Third Parties. The Sellers agree to cooperate with the Buyer, at the Buyer’s reasonable request, in the
notification to third parties of the transactions contemplated by this Agreement and the Sellers
agree not to notify any third parties of such transactions without the consent of the Buyer.

     Section 6.7 Patent Maintenance. After the Closing Date, the Buyer shall assume the duty to make all required maintenance and
prosecution payments as to the Product Patents for the remaining terms thereof; provided, however,
that upon ninety (90) days written notice, the Buyer may transfer any of the Product Patents to the
Patent Transferor from which the Buyer purchased such Product Patent in lieu of making further
maintenance or prosecution payments. Nothing in this Section 6.7 shall obligate the
Sellers to assume any further maintenance or prosecution payments.

ARTICLE 7

CONDITIONS TO CLOSING

     Section 7.1 Conditions Precedent to Buyer’s Obligations. Buyer’s obligations to consummate the transactions contemplated by this Agreement and the
Ancillary Agreements shall be subject to the fulfillment of each of the following additional
conditions, any one or more of which may be waived, at Buyer’s sole discretion, in writing by the
Buyer:

     (a) Representations and Warranties.

          (i) Each of the representations and warranties of the Sellers set forth in this Agreement, or
in any written statement or certificate that shall be delivered to the Buyer by the Sellers under
this Agreement (including the Officer’s Certificate) that is not qualified by “Material Adverse
Effect” or other materiality qualifications shall have been true and correct in all material
respects as of the date of this Agreement and shall be true and correct in all material respects as
of the Closing Date as if made at the Closing Date (except to the extent such representation or
warranty specifies an earlier date, in which case such representation or warranty shall be true and
correct in all material respects as of such date); and

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-24-

 

          (ii) Each of the representations and warranties of the Sellers set forth in this Agreement, or
in any written statement or certificate that shall be delivered to the Buyer by the Sellers under
this Agreement (including the Officer’s Certificate) that is qualified by “Material Adverse Effect”
or other materiality qualifications shall have been true and correct in all respects as of the date
of this Agreement and shall be true and correct in all respects as of the Closing Date as if made
at the Closing Date (except to the extent such representation or warranty specifies an earlier
date, in which case such representation or warranty shall be true and correct in all respects as of
such date).

     (b) Performance of Obligations. Each Seller shall have performed in all material
respects all obligations and covenants required to be performed by it under this Agreement and any
other agreement or document entered into in connection herewith prior to the Closing Date (to the
extent such obligations and covenants require performance prior to such time).

     (c) Release of Liens. The Buyer shall have received evidence satisfactory to it from
any Person who held any Encumbrance (other than Permitted Encumbrances) on any of the Purchased
Assets of the release by such Person of such Encumbrance effective upon or concurrent with the
Closing.

     (d) Legal Requirements. No Law shall be in effect which prohibits or materially
restricts the consummation of the Transactions contemplated by this Agreement and the Ancillary
Agreements at the Closing, or which otherwise adversely affects in any material respect the right
or ability of the Buyer to own, operate or control the Purchased Assets, in whole or material part,
and no Action is pending or threatened by or before a Governmental Authority which, if successful,
could reasonably be expected to result in a Law having such effect or which seeks to obtain from
the Buyer any damages.

     (e) Closing Deliveries. The Sellers shall have delivered to the Buyer all of the
closing documents and agreements set forth in Sections 3.2 and 3.4, and each of
such documents and agreements shall be in full force and effect.

     (f) FIRPTA Compliance. The Sellers shall have delivered to the Buyer the certificate
referred to in Section 6.5(d).

     (g) Termination or Release of Third Party Finders Agreements. The Buyer shall have
received evidence satisfactory to it that all agreements relating to the payment of finder’s fees,
brokerage fees, commissions or similar payments in connection with the Sellers’ entry into this
Agreement or the consummation of the transaction contemplated hereby have been terminated or
released with respect thereto have been granted such that the Buyer will not have any Liability
under such agreements.

     Section 7.2 Conditions Precedent to Sellers’ Obligations. The Sellers’ obligation to consummate the transactions contemplated hereby shall be subject to
the fulfillment of each of the following additional conditions, any one or more of which may be
waived, at the Sellers’ sole discretion, in writing by the Sellers:

     (a) Representations and Warranties.

          (i) Each of the representations and warranties of the Buyer set forth in this Agreement, or in
any written statement or certificate that shall be delivered to the Sellers by the Buyer under this
Agreement that is not qualified by “Material Adverse Effect” or other materiality qualifications
shall have been true and correct in all material respects as of the date of this Agreement and
shall be true and correct in all material respects as of the Closing Date as if made at the Closing
Date (except to the extent such representation or warranty specifies an earlier date, in which case
such representation or warranty shall be true and correct in all material respects as of such
date); and

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-25-

 

          (ii) Each of the representations and warranties of the Buyer set forth in this Agreement, or
in any written statement or certificate that shall be delivered to the Sellers by the Buyer under
this Agreement that is qualified by “Material Adverse Effect” or other materiality qualifications
shall have been true and correct in all respects as of the date of this Agreement and shall be true
and correct in all respects as of the Closing Date as if made at the Closing Date (except to the
extent such representation or warranty specifies an earlier date, in which case such representation
or warranty shall be true and correct in all respects as of such date).

     (b) Performance of Obligations. The Buyer shall have performed in all material
respects all obligations and covenants required to be performed by it under this Agreement and any
other agreement or document entered into in connection herewith prior to the Closing Date (to the
extent such obligations and covenants require performance prior to such time).

     (c) Closing Deliveries. The Buyer shall have delivered to the Sellers all of the
closing documents and agreements set forth in Section 3.4.

     (d) Legal Requirements. No Law shall be in effect which prohibits or materially
restricts the consummation of the Transactions contemplated by this Agreement and the Ancillary
Agreements at the Closing, or which otherwise adversely affects in any material respect the right
or ability of the Buyer to own, operate or control the Purchased Assets, in whole or material part,
and no Action is pending or threatened by or before a Governmental Authority which, if successful,
could reasonably be expected to result in a Law having such effect or which seeks to obtain from
the Buyer any damages.

ARTICLE 8

INDEMNIFICATION

     Section 8.1 Survival of Representations and Warranties.

     (a) All representations and warranties of the Sellers in this Agreement shall survive the
Closing until the 18-month anniversary of the Closing Date (the “Survival Date”);
provided, that:

          (i) the representations and warranties contained in Section 4.2, Section 4.6
and Section 4.7 shall survive until the expiration of the applicable statutes of
limitations relating to such representations and warranties; and

          (ii) any claim for indemnification based upon a breach of any such representation or warranty
and asserted prior to the Survival Date (or, in the case of any representation or warranty
contained in Section 4.2, Section 4.6 and Section 4.7, prior to the
expiration of the applicable statute of limitation relating to such representation or warranty) by
written notice in accordance with Section 8.2 shall survive until final resolution of such
claim.

     (b) The representations and warranties contained in this Agreement (and any right to
indemnification for breach thereof) shall not be affected by any investigation, verification or
examination by any Party hereto or by any Representative of any such Party or by any such Party’s
constructive knowledge (which, for purposes of clarity, excludes actual knowledge) of any facts
with respect to the accuracy or inaccuracy of any such representation or warranty.

     (c) The representations and warranties of the Buyer in Article V of this Agreement
shall terminate upon the Closing. For avoidance of doubt, the covenants of the Buyer shall survive
closing and remain in effect until satisfied or terminated.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-26-

 

     Section 8.2 Indemnification.

     (a) Sellers’ Indemnification Obligations. The Sellers shall, jointly and severally,
indemnify, save and hold harmless the Buyer, its Affiliates and their respective Representatives
from and against any and all costs, losses, Taxes, Liabilities, obligations, damages, lawsuits,
judgments, settlements, awards, deficiencies, claims, demands, expenses (including reasonable costs
of investigation and reasonable attorneys’ fees and expenses), interest, fines, penalties, costs of
mitigation, and other losses actually paid to third parties (herein, “Damages”), incurred
in connection with, arising out of, resulting from or incident to (i) any breach of a
representation or warranty of any Seller contained in this Agreement; (ii) any breach of any
covenant of any Seller contained in this Agreement; or (iii) any Excluded Asset or Excluded
Liability.

          The term “Damages” as used in this Article 8 is not limited to matters asserted by
third parties against the Sellers or the Buyer, but includes Damages incurred or sustained by the
Sellers or the Buyer in the absence of third party claims. Payments by the Buyer of amounts for
which the Buyer is indemnified hereunder, and payments by the Sellers of amounts for which the
Sellers are indemnified hereunder, shall not be a condition precedent to recovery. The Sellers’
obligation to indemnify the Buyer, and the Buyer’s obligation to indemnify the Sellers, shall not
limit any other rights, including without limitation rights of contribution which any Party may
have under statute or common law.

     (b) Buyer’s Indemnification Obligations. The Buyer shall indemnify and save and hold
harmless the Sellers, their respective Affiliates, and their Representatives from and against any
and all Damages incurred in connection with, arising out of, resulting from or incident to (i) any
breach of any representation or warranty made by the Buyer contained in this Agreement; (ii) any
breach of any covenant made by the Buyer contained in this Agreement; or (iii) from and after the
Closing, any Assumed Liability.

     (c) Defense of Claims. If a claim for Damages (a “Claim”) is to be made by a
Party entitled to indemnification (“Indemnified Party”) hereunder against the Party from
whom indemnification is sought (the “Indemnifying Party”), the Party claiming such
indemnification shall, subject to this Section 8.2, give written notice (a “Claim
Notice”) to the Indemnifying Party as soon as practicable after the Party entitled to
indemnification becomes aware of any fact, condition or event which may give rise to Damages for
which indemnification may be sought under this Section 8.3. If any lawsuit or enforcement
action is filed against any Party entitled to the benefit of indemnity hereunder, written notice
thereof shall be given to the Indemnifying Party as promptly as practicable (and in any event
within fifteen (15) calendar days after the service of the citation or summons). The failure of
any Indemnified Party to give timely notice hereunder shall not affect rights to indemnification
hereunder, except to the extent that the Indemnifying Party demonstrates actual damage caused by
such failure. After such notice, if the Indemnifying Party shall acknowledge in writing to the
Indemnified Party that the Indemnifying Party shall be obligated under the terms of its indemnity
hereunder in connection with such lawsuit or action, then the Indemnifying Party shall be entitled,
if it so elects at its own cost, risk and expense, (i) to take control of the defense and
investigation of such lawsuit or action, (ii) to employ and engage attorneys of its own choice to
handle and defend the same unless the named parties to such action or proceeding include both the
Indemnifying Party and the Indemnified Party and the Indemnified Party has been advised in writing
by counsel that there may be one or more legal defenses available to such Indemnified Party that
are different from or additional to those available to the Indemnifying Party, in which event the
Indemnified Party shall be entitled, at the Indemnifying Party’s cost, risk and expense, to
separate counsel of its own choosing, and (iii) to compromise or settle such claim, which
compromise or settlement shall be made only with the written consent of the Indemnified Party, such
consent not to be unreasonably withheld; provided, however, that this sentence
shall not apply to Claims relating to Taxes. If the Indemnifying Party fails to assume the defense
of such claim within fifteen (15) calendar days after

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-27-

 

receipt of the Claim Notice, the Indemnified Party against which such claim has been asserted will
(upon delivering notice to such effect to the Indemnifying Party) have the right to undertake, at
the Indemnifying Party’s cost and expense, the defense, compromise or settlement of such claim on
behalf of and for the account and risk of the Indemnifying Party. In the event the Indemnified
Party assumes the defense of the claim, the Indemnified Party will keep the Indemnifying Party
reasonably informed of the progress of any such defense, compromise or settlement. The
Indemnifying Party shall be liable for any settlement of any action effected pursuant to and in
accordance with this Section 8.2 and for any final judgment (subject to any right of
appeal), and the Indemnifying Party agrees to indemnify and hold harmless the Indemnified Party
from and against any Damages by reason of such settlement or judgment.

     (d) Cooperation. The Indemnified Party shall cooperate in all reasonable respects
with the Indemnifying Party and such attorneys in the investigation, trial and defense of such
lawsuit or action and any appeal arising therefrom; provided, however, that the
Indemnified Party may, at its own cost, participate in the investigation, trial and defense of such
lawsuit or action and any appeal arising therefrom. For the avoidance of doubt, nothing contained
in this Section 8.2(d) shall affect the Indemnified Party’s right to employ and engage
separate counsel in accordance with Section 8.2(c)(ii). The Parties shall cooperate with
each other in any notifications to insurers.

     (e) Equitable Relief; No Waiver. Nothing in this Agreement shall (i) limit the right
of any Party to seek specific performance of, or equitable relief with respect to, another Party
with respect to a breach of any covenant or agreement set forth in this Agreement or (ii) be deemed
a waiver by any Party to this Agreement of any right or remedy which such Party may have at law or
in equity based on any claim of fraud.

     Section 8.3 Right of Setoff. The Buyer may setoff any amount to which it is
entitled under Section 6.5(e) or this Article 8 against amounts otherwise payable to the
Sellers hereunder, provided that any amount to be setoff is no greater than any amount to which the
Buyer is entitled to under Section 6.5(e) and this Article 8. Neither the exercise nor the
failure to exercise such right of setoff shall constitute an election of remedies or limit the
Buyer in any manner in the enforcement of any other remedies that may be available to it.

ARTICLE 9

MISCELLANEOUS PROVISIONS

     Section 9.11 Confidentiality and Publicity.

     (a) The Mutual Confidentiality and Disclosure Agreement, attached as Exhibit A to the Existing
License Agreement is hereby incorporated in this Agreement as though fully set forth herein. All
terms used in this Section 9.1 and not otherwise defined herein shall have the meanings
assigned to such terms in the Confidentiality Agreement. Subject to this Section 9.1, all
information exchanged between or among the Parties prior to, on and after the date of this
Agreement shall be subject to and treated in accordance with the terms and conditions of the
Confidentiality Agreement. The Parties agree that from and after the Closing Date, the
Confidentiality Agreement shall remain in full force and effect pursuant to its terms with respect to all Confidential Information that does not relate to the
Purchased Assets or the Assumed Liabilities.

     (b) From and after the Closing Date, all Confidential Information primarily concerning the
Purchased Assets and the Assumed Liabilities (the “Buyer Proprietary Information”) shall be
used by the Sellers solely as required to perform their respective obligations, exercise or enforce
their respective rights under this Agreement (or any Ancillary Agreement), or comply with
applicable Law, and for no other purpose. The Sellers shall not disclose, or permit the disclosure
of, any of the Buyer Proprietary

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-28-

 

Information to any Person except those Persons to whom such
disclosure is necessary to permit the Sellers to perform their respective obligations, exercise or
enforce their respective rights under this Agreement (or any Ancillary Agreement), or comply with
applicable Law. The Sellers shall treat, and will cause their respective Affiliates and the
Representatives and advisors of the Sellers or any of their respective Affiliates to treat, the
Buyer Proprietary Information as confidential, using the same degree of care as the Sellers
normally employ to safeguard its own confidential information from unauthorized use or disclosure,
but in no event less than a reasonable degree of care.

     (c) All Confidential Information obtained by the Buyer (or its Representatives or Affiliates)
from the Sellers (or its Representatives or Affiliates) other than the Buyer Proprietary
Information (the “Sellers’ Proprietary Information”) shall be used by the Buyer solely as
required to perform its obligations, exercise or enforce its rights under this Agreement (or any
Ancillary Agreement), or comply with applicable Law, and for no other purpose. The Buyer shall not
disclose, or permit the disclosure of, any of the Sellers Proprietary Information to any person
except those persons to whom such disclosure is necessary to permit the Buyer to perform its
obligations, exercise or enforce its rights under this Agreement (or any Ancillary Agreement), or
comply with applicable Law. The Buyer shall treat, and will cause its Affiliates and the
Representatives and advisors of the Buyer or any of their respective Affiliates to treat, the
Sellers’ Proprietary Information as confidential, using the same degree of care as the Buyer
normally employ to safeguard its own confidential information from unauthorized use or disclosure,
but in no event less than a reasonable degree of care.

     (d) In the event either Party is requested pursuant to, or required by, applicable Law to
disclose any of the other Party’s Confidential Information (i.e., the Sellers’ Proprietary
Information or the Buyer Proprietary Information, as applicable), it will notify the other Party in
a timely manner so that such Party may seek a protective order or other appropriate remedy or, in
such Party’s sole discretion, waive compliance with the confidentiality provisions of this
Agreement. Each Party will cooperate in all reasonable respects, in connection with any reasonable
actions to be taken for the foregoing purpose. In any event, the Party requested or required to
disclose such Confidential Information may furnish it as requested or required pursuant to
applicable Law (subject to any such protective order or other appropriate remedy) without liability
hereunder, provided that such Party furnishes only that portion of the Confidential
Information which such Party is advised by a reasoned opinion of its counsel is legally required,
and such Party exercises reasonable efforts to obtain reliable assurances that confidential
treatment will be accorded such Confidential Information.

     (e) Except as required by applicable Laws, no Party to this Agreement shall issue any press
release or make any public statement regarding the transactions contemplated hereby without the
prior approval of the other Parties, and the Parties shall issue a mutually acceptable press
release as soon as practicable after the Closing Date. Notwithstanding the foregoing, the Buyer
shall be permitted to make any public statement without obtaining the consent of the Sellers if (i)
the disclosure is required by applicable Laws or the requirements of the SEC or NASDAQ Stock Market
and (ii) the Buyer has first used its reasonable efforts to consult with (but not to obtain the
consent of) the Sellers about the form and substance of such disclosure.

     Section 9.2 Notices. Unless otherwise provided herein, any notice, request,
instruction or other document to be given hereunder by any Party to the other shall be in writing
and delivered in person or by courier, sent by facsimile transmission, sent via overnight delivery
service or mailed by registered or certified mail (such notice to be effective upon receipt), as
follows:

     If to the Sellers, addressed to:

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-29-

 

KDL GmbH

Bahnhofstrasse 7

CH-6301 Zug

Switzerland

Attn: Kjell H. Gaustad

Telephone: +41 61 403 0960

Fax: +41 61 403 0961

with a copy to:

Shitotomo Yamauchi, Ph.D.

2-21-14 — # 403

Shimo-ochai, Shinjuku

Tokyo 161-0033, Japan

Japan

Telephone: +81 3 5996 3633

Fax: +81 3 5996 9555

If to the Buyer, addressed to:

InterMune, Inc.

3280 Bayshore Boulevard

Brisbane, CA 94005

Attn: General Counsel

Telephone: (415) 466-2200

Fax: (415) 466-2300

with a copy to:

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Attn: Mark V. Roeder

Telephone: (650) 328-4600

Fax: (650) 463-2600

or to such other place and with such other copies as any Party may designate as to itself by
written notice to the other Parties.

     Section 9.3 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
California without regard to the conflicts of laws principles thereof that would require the
application of the laws of any other jurisdiction.

     Section 9.4 Representation By Counsel. Each Party hereto represents and agrees
with each other that it has been represented by or had the opportunity to be represented by,
independent counsel of its own choosing, and that it has had the full right and opportunity to
consult with its respective attorney(s), that to the extent, if any, that it desired, it availed
itself of this right and opportunity, that it or its authorized officers (as the case may be) have
carefully read and fully understand this Agreement in its entirety and have had it fully explained
to them by such Party’s respective counsel, that each is fully aware of the contents thereof and
its meaning, intent and legal effect, and that it or its authorized officer

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-30-

 

(as the case may be) is
competent to execute this Agreement and has executed this Agreement free from coercion, duress or
undue influence.

     Section 9.5 Expenses. Except as expressly provided for herein, all expenses,
including the fees of any attorneys, accountants, investment bankers, brokers, finders or others
engaged by a Party, incurred in connection with this Agreement, the Ancillary Agreements and the
transactions contemplated hereby and thereby, shall be paid by the Party incurring such expenses.

     Section 9.6 Entire Agreement. This Agreement (including the documents and the
instruments referred to herein) and the Confidentiality Agreement constitute the entire agreement
among the Parties pertaining to the subject matter hereof and supersede all prior agreements,
understandings, negotiations and discussions, whether written and oral, among the Parties.

     Section 9.7 Amendment; Waiver. This Agreement may not be amended except in an
instrument in writing signed on behalf of each of the Parties hereto. No amendment, supplement,
modification or waiver of this Agreement shall be binding unless executed in writing by the Party
to be bound hereby. No waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of any other provision hereof (whether or not similar), nor shall such waiver
constitute a continuing waiver unless otherwise expressly provided.

     Section 9.8 Severability. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced as a result of any rule of law or public policy,
all other terms and other provisions of this Agreement shall nevertheless remain in full force and
effect so long as the economic or legal substance of the transactions contemplated by this
Agreement is not affected in any manner materially adverse to any Party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the Parties
hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent
of the Parties as closely as possible in an acceptable manner to the end that the transactions
contemplated by this Agreement are fulfilled to the greatest extent possible.

     Section 9.9 Assignment. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be
assigned by any of the Parties hereto (whether by operation of law or otherwise) without the prior
written consent of the other Parties hereto; provided, however, that such written
consent will not be required by an assignment by the Buyer (a) to any of its Affiliates (in which
case the Buyer shall remain liable for all obligations of the Buyer hereunder, including the
performance or nonperformance of any actions or omissions of its Affiliates) or (b) in connection
with a merger, sale or transfer involving all or substantially all of the assets of the Buyer.
Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and
be enforceable by the Parties and their respective permitted successors and assigns.

     Section 9.10 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which shall constitute
one and the same agreement. Each of the Parties agrees to accept and be bound by facsimile
signatures hereto.

     Section 9.11 Waiver of Jury Trial. Each signatory to this Agreement hereby waives
its respective right to a jury trial of any permitted claim or cause of action arising out of this
Agreement, any of the transactions contemplated hereby, or any dealings between any of the
signatories hereto relating to the subject matter of this Agreement or any of the transactions
contemplated hereby. The scope of this waiver is intended to be all encompassing of any and all
disputes that may be filed in any court and that relate to the subject matter of this agreement or
any of the transactions contemplated hereby, including, without limitation, contract claims, tort
claims, and all other common law and statutory claims. This

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-31-

 

waiver is irrevocable, meaning that it
may not be modified either orally or in writing, and this waiver shall apply to any subsequent
amendments, supplements or other modifications to this agreement, any of the transactions
contemplated hereby or to any other document or agreement relating to the transactions contemplated
hereby.

     Section 9.12 Consent to Jurisdiction. EACH PARTY HERETO IRREVOCABLY AND
UNCONDITIONALLY (I) AGREES THAT ANY SUIT, ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF THIS
AGREEMENT MAY BE BROUGHT IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF
CALIFORNIA OR, IF SUCH COURT DOES NOT HAVE JURISDICTION OR WILL NOT ACCEPT JURISDICTION, IN ANY
COURT OF GENERAL JURISDICTION IN THE COUNTY OF SAN FRANCISCO, CALIFORNIA; (II) CONSENTS TO THE
JURISDICTION OF ANY SUCH COURT IN ANY SUCH SUIT, ACTION OR PROCEEDING; AND (III) WAIVES ANY
OBJECTION WHICH SUCH PARTY MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH SUIT, ACTION OR PROCEEDING
IN ANY SUCH COURT.

     Section 9.13 Attorney Fees. If any Party to this Agreement brings an Action to
enforce its rights under this Agreement in accordance with the provisions hereof, the prevailing
Party shall be entitled to recover its actual out-of-pocket costs and expenses, including without
limitation reasonable attorneys’ fees reasonably incurred in connection with such Action, including
any appeal of such Action.

     Section 9.14 Remedies Cumulative; Specific Performance. The rights and remedies of
the Parties hereto shall be cumulative (and not alternative). The Parties agree that, in the event
of any breach or threatened breach by any Party of any covenant, obligation or
other provision set forth in this Agreement for the benefit of any other Party, such other Party
shall be entitled (in addition to any other remedy that may be available to it) to (a) a decree or
order of specific performance or mandamus to enforce the observance and performance of such
covenant, obligation or other provision, and (b) an injunction restraining such breach or
threatened breach.

     Section 9.15 Time is of Essence. Time is of the essence with respect to the
performance of this Agreement.

     Section 9.16 Executory Nature of the Duties Imposed by this Agreement. This
Agreement is intended to require the Sellers and the Buyer to perform a number of executory duties
throughout the term of this Agreement. The Parties intend that this Agreement shall be governed by
Section 365 of the Bankruptcy Code.

     Section 9.17 Bankruptcy Rights. In the event this Agreement is terminated or
rejected by either the Buyer or any Seller or the Buyer’s or any Seller’s trustee or debtor in
possession in bankruptcy (or receiver) under applicable bankruptcy or receivership laws due to the
Buyer or such Seller’s bankruptcy or receivership, then all rights and licenses granted by the
Sellers to the Buyer and by the Buyer to the Sellers shall be deemed to be, for purposes of Section
365(n) of the Bankruptcy Code and any other similar law or regulation in any other country,
licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy
Code. The parties intend such rights and licenses to be subject to the protections afforded the
non-terminating party under Section 365(n) of the Bankruptcy Code or any similar law or regulation
in any other country.

     Section 9.18 Release. Each Party hereby releases the other Party, its
successors and assigns, and their respective Representatives, in each case from and against any and
all grievances, rights, actions, causes of action, claims, demands, complaints, obligations,
liabilities or controversies of any and all kinds, nature and character whatsoever, legal and
equitable, whether known or unknown, foreseen or unforeseen, that a Party has or shall or may have
under any Law, arising out of, related to, or in

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-32-

 

connection with the Existing License Agreements
(the “Released Claims”). EACH PARTY HEREBY EXPRESSLY WAIVES THE BENEFIT OF ANY STATUTE OR
RULE OF LAW THAT, IF APPLIED TO THIS AGREEMENT, WOULD OTHERWISE EXCLUDE FROM ITS BINDING EFFECT ANY
RELEASED CLAIMS NOT KNOWN BY SUCH PARTY TO EXIST WHICH AROSE PRIOR TO THE SIGNING OF THIS
AGREEMENT. Each Party understands and acknowledges that it may not currently know of losses or
claims or may have underestimated the severity of losses. Part of the consideration provided by
this Agreement was given in exchange for the release of such claims. Each Party hereby waives any
rights or benefits under California Civil Code Section 1542 (or any similar statute in any other
jurisdiction), which provides that: “A general release does not extend to claims which the
creditor does not know or suspect to exist in his favor at the time of executing the release, which
if known by him must have materially affected his settlement with debtor.”

[SIGNATURE PAGE FOLLOWS]

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

-33-

 

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the
date first above written.

	 	 	 	 	 	 	 
	 	 	BUYER	 	 
	 
	 	 	 	 	 	 
	 	 	INTERMUNE, INC.	 	 
	 
	 	 	 	 	 	 
	 	 	/s/ Daniel G. Welch	 	 
	 	 	 	 	 
	 

	 	By:
	 	Daniel G. Welch	 	 
	 

	 	Its:
	 	President and CEO	 	 
	 
	 	 	 	 	 	 
	 	 	SELLERS	 	 
	 
	 	 	 	 	 	 
	 	 	KDL GmbH	 	 
	 
	 	 	 	 	 	 
	 

	 	/s/ Kjell H. Gaustad	 	 
	 

	 	By:
	 	 

Kjell H. Gaustad
	 	 
	 

	 	Its:
	 	Managing Director	 	 
	 
	 	 	 	 	 	 
	 

	 	/s/ Shitotomo Yamauchi	 	 
	 

	 	 

DR. Shitotomo Yamauchi
	 	 

SIGNATURE PAGE TO KDL APA

[ * ] = Certain information on this page has been redacted and filed separately with the
Securities and Exchange Commission.
Confidential treatment has been requested
with respect to the omitted portions.exv10w61

 

[ * ] =Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

EXHIBIT 10.61

LICENSE AGREEMENT

     THIS LICENSE AGREEMENT is made and entered into as of August 24, 2004 (the “Effective Date”)
by and between InterMune, Inc., a Delaware corporation having its principal place of business at
3280 Bayshore Blvd., Brisbane, California 94005 (“Licensee”), and Chiron Corporation, a Delaware
corporation having its principal place of business at 4560 Horton Street, Emeryville, California
94608 (“Chiron”).

BACKGROUND

     WHEREAS, Chiron has developed certain intellectual property rights with respect to Hepatitis C
Virus (“HCV” as hereinafter defined) which relate to the HCV genome and encoded proteins;

     WHEREAS, Licensee desires to be engaged in the research and development of small molecule
inhibitors of the HCV genome and encoded proteins and related therapeutics for the treatment of HCV
infection, which activities fall within the scope of the Chiron Patent Rights (as hereinafter
defined);

     WHEREAS, Licensee wishes to obtain a license under the Chiron Patent Rights for such purposes;
and

     WHEREAS, Chiron is willing to grant, and has offered to grant Licensee a license under the
Chiron Patent Rights for a negotiable fully paid-up, one-time fee; and

     WHEREAS, as an alternative to the arrangement whereby Licensee would secure a license under
the Chiron Patent Rights for a fully paid up one time fee, Licensee wishes to enter into an
arrangement pursuant to which Licensee shall provide consideration for the license under Chiron
Patent Rights by paying to Chiron up-front fees, [ * ], milestone and royalty payments, which
payments represent Chiron’s interest in the value contributed by the licensure of Chiron Patent
Rights to Licensee’s program(s) for the research, development and commercialization of Identified
Products, as hereinafter defined.

     NOW, THEREFORE, in consideration of the above premises and the mutual covenants contained
herein, the parties hereto agree as follows:

1. DEFINITIONS

     For the purposes of this Agreement, the following definitions shall apply, and the terms
defined herein in plural shall include the singular and vice-versa:

     1.1. “Affiliate” means, with respect to a party hereto, any corporation, partnership, joint
venture or other business arrangement which is controlled by, controlling or under common control
with such party, and shall include without limitation any direct or indirect

1

 

beneficial ownership
of more than fifty percent (50%) of the voting stock or participating profit interest of such
corporation or other business entity. Without limiting the generality of the foregoing, the
Affiliates of Chiron expressly exclude Novartis A.G, a Swiss corporation, and any Affiliate thereof
not otherwise an Affiliate of Chiron (collectively, “Novartis”) unless and until such time as
Novartis exercises its rights to control Chiron in accordance with the terms and conditions of the
November 20, 1994 Governance Agreement between Chiron and Novartis’ predecessor in interest,
Ciba-Geigy Limited.

     1.2. “Chiron Patent Rights” means the patents or patent applications owned by Chiron
listed in Exhibit A attached hereto and incorporated herein, together with all patents issuing
thereon, including any divisionals, continuations, continuations-in-part, reissues, reexaminations
and extensions thereof, and foreign counterparts.

     1.3. “FDA” means the United States Food and Drug Administration and any successor drug
regulatory entity thereto.

     1.4. “HCV” means the Hepatitis C virus, including any isolates, strains or mutations
thereof.

     1.5. “Identified Products” means compounds that act on, whether by modulation,
stimulation, inhibition, or otherwise:

     1.5.1.
the HCV [  *  ] with respect to which Licensed Processes
were employed at any time during the course of the research, development or
commercialization of such compounds; or

     1.5.2.
[  *  ], with respect to which Licensed Processes
were employed at any time during the course of the research, development or
commercialization of such compounds; or

     1.5.3.
HCV  which    [  *  ]  compounds (a) [  *  ] compounds defined by 1.5.1
or 1.5.2 above [  *  ]  Licensed Processes were utilized at any time during
the course of the research, development or commercialization of such compounds; [  *  ]  (b)
[  *  ]  activity
that would infringe the Chiron Patent Rights but for the rights granted hereunder.

     1.6. “IND” means a “Notice of Claimed Investigational Exemption for a New Drug” filed
with the FDA, as defined in 21 C.F.R. Part 312, or foreign equivalent thereof.

     1.7. “Licensee Confidential Information” means Licensee’s confidential and/or
proprietary information relating to any Identified Product, including but not limited to Licensee’s
know-how, invention disclosures, technology, libraries, targets, compounds, patents, proprietary

[ * ] = Certain information on this page has been redacted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

-2-

 

materials and/or technologies, economic information, business or research strategies, trade secrets
and material embodiments thereof.

     1.8. “Licensee Facility” means and is limited to the facilities of Licensee and its
Affiliates located at the locations specified in Exhibit B attached hereto and incorporated herein
and such other locations as Licensee may designate in writing from time to time to Chiron.
Licensee may add additional locations to this list with Chiron’s prior written consent, which
consent shall not be unreasonably withheld and, upon such consent, such additional locations shall
be a Licensee Facility for purposes of this Agreement.

     1.9. “Licensed Composition” means any composition, the making, using, selling,
keeping, offering for sale, importing or exporting thereof would, but for the license granted
herein, infringe any Valid Claim within Chiron Patent Rights, if practiced in a Reference Country.

     1.10. “Licensed Method” means any method or process, the practice of which would, but
for the license granted herein, infringe a Valid Claim of the Chiron Patent Rights, (including,
without limitation, the manufacture, use, sale, keeping, offer for sale, importation or exportation
of a product which would infringe any such Valid Claim), if practiced in a Reference Country.

     1.11. “Licensed Processes” means any process that involves the use, practice or
manufacture of a Licensed Composition and/or Licensed Method, including without limitation:
[ * ].

     1.12. “Licensed Territory” means (a) for purposes of use of the Licensed Processes,
any country in the world where Licensee has a Licensee Facility; and (b) for purposes of
development and commercialization of Identified Products means worldwide.

     1.13. “NDA” means an application submitted to the FDA or foreign equivalent thereof,
which contains the details of the manufacture and testing of a new drug for purposes of obtaining
regulatory approval to market such new drug.

     1.14. “Net Sales" shall be calculated in accordance with U.S. generally accepted
accounting principles and means the gross amount billed or invoiced for sales or other dispositions
of all Identified Products hereunder (other than sales or other dispositions to Affiliates unless
such Affiliate is the end user), less the following deductions actually paid or
incurred (to the extent they are not already reflected in the amount invoiced and to the
extent they are not otherwise covered or reimbursed): (a) discounts, returns, allowances, Medicaid
rebates, and wholesaler chargebacks allowed and taken in amounts customary in the trade; (b)
import, export, excise, sales or use taxes, value added taxes, and other taxes, tariffs or duties
directly imposed and properly allocable to Identified Product sales, but not taxes assessed on
income derived from Identified Product sales; (c) separately itemized shipping, freight charges or
insurance paid; and (d) amounts allowed or credited for retroactive price reductions or rebates.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-3-

 

Where Identified Product is sold in the form of a combination product containing one or more active
ingredients in addition to an Identified Product, Net Sales for such combination product will be
calculated by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B)
where A is the invoice price of the Identified Product if sold separately, and B is the total
invoice price of any other active component or components, or devices, in the combination, if sold
separately. If, on a country-by-country basis, the other active component or components in the
combination are not sold separately in said country, Net Sales for the purpose of determining
royalties of the combination product shall be calculated by multiplying actual Net Sales of such
combination product by the fraction A/C where A is the invoice price of the Identified Product, if
sold separately, and C is the invoice price of the combination product. If, on a
country-by-country basis, neither the Identified Product nor the other active component or
components of the combination product is sold separately in said country, Net Sales for the
purposes of determining royalties of the combination product shall be determined by the parties by
mutual agreement.

If Licensee receives any consideration for the sale or other disposal of any Identified Product
or for the use of any Identified Product other than monetary consideration under bona fide
arm’s length terms, then for the purposes of calculating the royalty payable under this
Agreement, such Identified Products shall be deemed to be sold exclusively for money at the
fair market price generally achieved for such Identified Products in the country in which such
sale or other disposal or use occurred when such Identified Products are sold alone and not
with other products.

     1.15. “Payment Term” shall have the meaning set forth in Section 8.2.

     1.16. “Phase I Clinical Trial” shall mean first human dosing, such as pursuant to a
clinical trial, conducted in accordance with 21 C.F.R. 312.21(a) or other applicable regulatory
requirements outside the United States, designed to establish the safety, and preliminary evidence
of effectiveness, of a pharmaceutical product for human use.

     1.17. “Phase II Clinical Trial” shall mean first human dosing pursuant to a clinical
trial, conducted in accordance with 21 C.F.R. 312.21(b) or other applicable regulatory requirements
outside the United States, of appropriate size and designed to evaluate the effectiveness of a
pharmaceutical product in patients with the disease for its intended use and in the dosage range to
be prescribed by identifying the proportion of patients within the trial who respond to the
pharmaceutical product.

     1.18. “Phase III Clinical Trial” shall mean first human dosing pursuant to a clinical
trial, conducted in accordance with 21 C.F.R. 312.21(c) or other applicable regulatory
requirements outside the United States, that is conducted after preliminary evidence
suggesting effectiveness has been obtained, that is of appropriate size and design to establish
that a pharmaceutical product is safe and effective for its intended use, to define warnings,
precautions and adverse reactions that are associated with the pharmaceutical product in the dosage
range to be prescribed, and to support regulatory approval of such pharmaceutical product or label
expansion of such pharmaceutical product.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-4-

 

     1.19.
“Reference Countries” means the
United States of America for any activities that
are conducted in the United States of America, and

[ * ] for any activities that are
conducted outside the United States of America.

     1.20. “Research and Development Field” means the research and development of
Identified Products. The Research and Development Field is limited to the research and development
of [ * ] HCV [ * ], and expressly excludes research and development
related to
[ * ]. Also excluded from the
Research and Development Field are the research and development of (i) 
[ * ] and (ii) 
[ * ].

     1.21. “Research and Development Term” shall have the meaning set forth in
Section 8.1.

     1.22. “[ * ]” means [ * ].

     1.23. “Valid Claim” means any claim of an issued (or granted) and unexpired patent
which has not been held unenforceable, unpatentable or invalid by a decision of a court or
governmental agency of competent jurisdiction, which decision is unappealable or unappealed within
the time allowed for an appeal, and which has not been admitted by Chiron to be invalid or
unenforceable generally through reissue or disclaimer.

2. LICENSE

     2.1. Research and Development License Grant. Subject to all of the terms and
conditions in this Agreement, Chiron hereby grants to Licensee and to its wholly owned subsidiaries
and to those of its Affiliates conducting research and development activities at the Licensee
Facilities and to other of its Affiliates approved in writing by Chiron, which approval shall not
be unreasonably withheld (collectively with Licensee, the “Licensed Entities”), a non-transferable,
non-exclusive license, without the right to sublicense (unless Chiron has consented to such
sublicense under Section 2.1(c) below), under the Chiron Patent Rights, to use Licensed
Compositions and Licensed Methods in the Research and Development Field at a designated Licensee
Facility in the Licensed Territory during the Research and Development Term and to make, have made,
use, have used, sell, have sold, import, and export Identified Products during the term of this
Agreement (the “License”). The License shall be solely for the benefit of:

          (a) Licensed Entities; or

          (b) Licensee and a bona fide third party collaborator of Licensee to whom Chiron has granted a
license under Chiron Patent Rights to practice Licensed Processes in the Research and Development
Field, as confirmed by Chiron’s prior written acknowledgement; or

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-5-

 

          (c) Licensee and any other third party bona fide research collaborator, provided (i) Licensee
has provided Chiron with prior written notice identifying such third party collaborator and the
scope of the collaboration and (ii) Chiron has provided prior written consent to Licensee providing
such third party the benefit of the License, such consent not to be unreasonably withheld or
delayed. For purposes of this provision, consent shall be favorably considered if, for example,
the third party collaborator is granted such benefit for research purposes only, is exclusive to
Licensee with regard to the benefit, retains no development or commercial rights to Identified
Products and ceases all such activities upon the termination of its relationship with Licensee.
Notwithstanding the foregoing, Chiron hereby acknowledges and consents to [ * ], provided that [ *
], further provided that [ * ], and still further provided that [ * ].

     2.2. Additional Licenses. For the avoidance of doubt, nothing in the foregoing shall
be construed as a restriction on any licensing, or otherwise granting or authorizing, by Licensee
of marketing, manufacturing, importing, exporting, distribution, development, selling or other
commercialization rights to any Identified Product to a third party, and any third party so
licensed shall be free to exercise any such rights without any further obligation to Chiron,
provided that the sale of such Identified Product (including an Identified Product in development)
by or through such third party remains subject to the payment, reporting and indemnity provisions
of this Agreement. Nothing in this paragraph is intended to grant to Licensee the right to
sublicense Chiron Patent Rights, Licensed Compositions or Licensed Methods to third parties.

     2.3. Prior Activity. For the avoidance of doubt, the foregoing and all subsequent
terms of this Agreement shall be construed to embrace and apply to any activity carried out by
Licensee, [ * ], prior to the Effective Date within the
Research and Development Field, which activity may fall within the scope of the Chiron Patent
Rights, provided however, that Licensee shall pay to Chiron within ten (10) days of the Effective
Date any and all payments, if any, which would have been due under Sections 3.1.3, 3.1.4 and 3.1.5
had the License been granted prior to the Effective Date. Any Identified Products subject to such
payment(s), including latest stage of clinical achievement for each such Identified Product, are
listed in Exhibit C attached hereto and incorporated herein. In the event that no such payments
are due and owing to Chiron pursuant to the prior sentence, Licensee hereby represents that it does
not have any products in development which, as of the Effective Date, would have triggered any
payments due under Sections 3.1.3, 3.1.4 and 3.1.5. Notwithstanding the foregoing, any rights
granted to Licensee pursuant to this Section 2.3 shall terminate as of the Effective Date in the
event of a termination of this Agreement by Chiron pursuant to Section 8.3.1(b) below.

     2.4. Use Limitations. Licensee shall not have any rights under the Chiron Patent
Rights other than those specified in Sections 2.1 and 2.2, all other rights being retained by
Chiron. Without limiting the foregoing, Licensee shall not use Licensed Processes outside the
Research and Development Field or for the benefit of any third party not permitted by Section 2.1.
In the event that [ * ], such Identified Products shall be subject to the milestone and royalty
provisions herein and Licensee shall [ * ]. Without limiting the foregoing, Chiron grants Licensee
no rights under the Chiron Patent Rights to make, have made, use, sell or otherwise

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-6-

 

[ * ]. Notwithstanding any other provision in this Section 2.4,
[ * ] shall have the right to
[ * ] in the Research and Development
Field.

     2.5. Marketing Arrangements. In connection with arrangements with third parties
whereby such third parties would distribute or market Identified Products, Licensee agrees to
comply and to cause such third parties to comply with all terms and conditions of this Agreement.
For the avoidance of doubt, neither Licensee nor any such third party that develops, distributes or
markets Identified Products shall be required to make duplicate payments for any one Identified
Product for which payment has been received by Chiron.

3. PAYMENTS

     3.1. Payments. In consideration of Chiron’s grant of the License to Licensee,
Licensee shall, in addition to the other Licensee obligations referenced herein, make to Chiron the
payments referenced in this Section 3.1.

          3.1.1 License Issuance Fee. Within thirty (30) days following the Effective Date,
Licensee shall pay to Chiron a non-refundable license issuance fee (the “Issuance Fee”) of Three
Hundred Seventy Five Thousand U.S. Dollars ($375,000).

          3.1.2 [ * ]. On [ * ] of the Effective Date during the Research & Development Term,
 [ * ], Licensee shall pay to Chiron
[ * ] (the “[ * ]”) in the amount of [ * ] U.S. Dollars ($[ * ]). The [ * ] shall be creditable
against royalty payments referenced in Sections 3.1.4 and 3.1.5, if any, for [ * ]. Royalty
payments payable in excess of the [ * ] shall not be creditable against any [ * ].

          3.1.3 Milestone Payments. With respect to each and every Identified Product developed
by (i) Licensed Entities; or [ * ] which reaches the milestone events referenced in this Section
3.1.3, Licensee shall pay to Chiron the following milestone payments:

               (a) Upon filing of an IND or commencement of Phase I Clinical Trials (or foreign equivalent),
whichever occurs first: $500,000; and

               (b) [ * ]; and

               (c) [ * ]; and

               (d) [ * ]; and

               (e) [ * ].

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-7-

 

          For the avoidance of doubt, each payment pursuant to clause (a), (b), (c), (d) or (e) above
shall be non-refundable, non-creditable, non-cancelable and payable once (and only once) with
respect to each Identified Product regardless of the number of countries in which clinical trials
are conducted or NDA or equivalent product registrations are filed or approved, and regardless of
how many NDA or equivalent product registrations are filed or approved in any country with respect
to such Identified Product. For the further avoidance of doubt, “commencement of Clinical Trial”
shall mean the date of first such dosing of Identified Product in humans as part of such trial.

          3.1.4 Royalty Payments for [ * ] Identified Product  [ * ]. Licensee shall,
until the expiration of the Payment Term, pay to Chiron, within [ * ] days after the end of each
calendar [ * ], an earned royalty equal to [ * ] percent ([ * ]%) of Net Sales of each Identified
Product that [ * ].

          3.1.5.
Royalty Payments for [ * ] Identified Products. Licensee shall, until the
expiration of the Payment term, pay to Chiron, within [ * ] days after the end of each calendar [ *
], an earned royalty equal to [ * ] percent ([ * ]%) of Net Sales of each Identified Product that [
* ].

     3.2. Manner of Payment. All payments hereunder shall be in United States dollars in
immediately available funds and shall be made by wire transfer to such bank account as may be
designated from time to time by Chiron.

          3.2.1 Exchange Rate. In the event that Identified Products are sold in currencies
other than United States dollars, Net Sales shall be calculated by Licensee in accordance with
generally accepted accounting principles. Net Sales in such other currencies shall be converted
into U.S. dollars at the end of each royalty reporting period using an exchange rate equal to the
simple average of the daily “U.S. dollar noon buying rates” on each business day of the applicable
royalty reporting period, as published at 12:00pm daily New York time by the Federal Reserve Bank
of New York (available on Bloomberg & Reuters). Royalty payments due to Chiron pursuant to
Sections 3.1.4 and 3.1.5 shall be calculated based on the Net Sales in United States dollars as
calculated above.

          3.2.2 Blocked Currency. In the event that restrictions or prohibitions imposed by a
national or international government authority preclude conversion of a national or international
currency into United States dollars, Licensee and Chiron shall consult to find a prompt and
acceptable solution and, prior to Licensee and Chiron determining such an acceptable solution,
Licensee shall handle all money received by Licensee from the sale or other distribution of
Identified Products as Chiron may lawfully direct. The cost and expense incurred as a consequence
of any such handling shall be borne equally by Licensee and Chiron. Notwithstanding the foregoing,
if any national or international currency cannot be converted into
United States dollars when payment to Chiron is due and payable under Section 3.1 above,
Licensee shall deposit the local currency equivalent of the United States dollar payment amount due
and payable to Chiron in an interest-bearing account in the name of Chiron. In the event that
conversion into United States dollars of any payment amount due and payable to Chiron deposited in
an interest-bearing account pursuant to the previous sentence becomes possible,

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-8-

 

Licensee shall
deliver such payment amount to Chiron promptly, however, if conversion of any such amount is not
possible within twelve (12) months after the date payment was due and payment to Chiron, Licensee
shall transfer to Chiron the amount deposited in the name of Chiron, together with all interest
accrued on the amount deposited after the date of deposit.

          3.2.3 Late Payment. Any payment, including, without limitation, royalty payments,
made by Licensee hereunder after the date such payment is due, shall bear interest at the lesser
of: (a) [ * ] basis points above the three (3) month United States Dollar LIBOR as published in the
Wall Street Journal on the day which is two business days prior to the date the payment is due, or
(b) the maximum rate permitted by applicable law (the “Interest Rate”). The Interest Rate shall be
calculated from the date payment was due until actually received by Chiron (the “Interest Period”)
based on actual number of days lapsed and a 360-day year. If the Interest Period extends beyond
three (3) months, at the beginning of each three (3) month interval, the Interest Rate will be
recalculated using the current three (3) month LIBOR, as described above, until the payment is
received.

          3.2.4 Underpayment. If an Inspection (as defined in Section 4.3 hereafter) reveals an
underpayment, then Licensee shall promptly make up such underpayment with interest at the Interest
Rate.

     3.3. Withholding Taxes. To the extent a statutory tax withholding obligation is
imposed by a governmental authority upon any payment due and payable hereunder, Licensee shall be
entitled to withhold from such payment to Chiron the amount, if any, of any tax assessed against
Licensee and actually withheld, provided that such tax is only for the account of Licensee and
evidence of the payment of such tax is promptly provided to Chiron. Licensee shall pay the amount
of such tax to the proper taxing authority and shall be entitled to deduct the amount of such tax
from the payment to be made by Licensee to Chiron. Licensee shall advise Chiron of any tax payment
made for the benefit of Chiron pursuant to this Section 3.3 and provide Chiron copies of tax
receipts for all taxes paid and deducted from the payment due and payable to Chiron, together with
copies of all pertinent communications from or with governmental authorities with respect thereto.
At Chiron’s reasonable request and at Chiron’s reasonable expense, Licensee shall reasonably assist
Chiron in any effort by Chiron in claiming any exemption from such deductions or withholdings under
any double taxation or similar agreement or treaty from time to time in force, and in minimizing
the amount required to be so withheld or deducted.

4. STATEMENTS, RECORDS AND INSPECTION

     4.1. Statements. All milestone and royalty payments made to Chiron hereunder shall be
accompanied by a written statement setting forth in reasonable detail the calculation thereof,
including, for example, in the case of royalty payments, the gross amount billed or invoiced by the
Licensee or an affiliate or commercial collaborators or any other third party for the sale or
distribution for the Identified Product, itemized deductions against such gross amount, and
Net Sales on a country-by country basis. Such statement shall contain reference to Net Sales by
territory in United States Dollars, as calculated by the method in Section 3.2.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-9-

 

     4.2. Record Keeping. Licensee shall keep and maintain, and shall cause its Affiliates
[ * ] to keep and maintain, complete and accurate books of account and
adequate records of all sales of Identified Products in sufficient detail to permit Chiron to
confirm the accuracy of reported royalties hereunder, including without limitation, general
accounting ledgers, invoice/sale registers, original invoices and shipping documents, tax returns,
inventory and manufacturing records, sublicense and distributor agreements and price lists, product
catalogs and other marketing materials, and shall retain such books and records for a period of
three years from the last day of the calendar quarter in which such sales were made.

     4.3. Inspection. Chiron may from time to time and at any reasonable time, not
exceeding once every twelve (12) months, use a Chiron auditor (or such firm of certified public
accountants (“auditor”) as Chiron may select), to inspect the books and records of the Licensee,
Licensee’s Affiliates [ * ], as the case may be, and records and books of
sublicensees, to the extent necessary in order to verify the accuracy of any report or payment made
under this agreement, or in the case of Licensee’s failure to make reports or pay royalties, to
obtain information as to the royalty payable for any such period, by Licensee to Chiron (within the
three (3) full-year period immediately preceding such audit) (the “Inspection”). Books and records
shall include but not be limited to: (a) Accounting General Ledgers (electronically if available);
(b) Invoice/Sales Registers; (c) Original Invoice and Shipping Documents; (d) Federal and State
Business Tax Returns; (e) Company Financial Statements; (f) Sales Analysis Reports; (g) Inventory
and or Manufacturing Records; (h) Sub-License and Distributor Agreements; and (i) Price Lists,
Product Catalogs and Other Marketing Materials. Licensee agrees to maintain such books and records
for a period of not less than [ * ] years from the date each royalty report is submitted to
Chiron. Such Inspection shall be at Chiron’s expense unless a royalty payment deficiency is
determined and such deficiency is [ * ] percent ([ *
]%) or greater, for any royalty reporting period
included in the examination. In such case the Licensee shall be responsible for reimbursing Chiron
for the examination fee and expenses charged by the auditor. Any underpayment as determined by the
auditor shall be paid promptly to Chiron and will bear interest in accordance with Section 3.2.3.
Licensee agrees to pay past due royalties for any royalty deficiency error as determined by the
auditor, which affects periods prior to the period under audit. Chiron and the auditor shall
maintain in confidence such Inspection and its resulting report. The auditor may from time to time
consult with Chiron and any of its employees or third party counsel on questions as they relate to
the licensed technology. The auditor may not disclose financial or proprietary information except
as required by the license agreement or if it already exists in the public domain.

5. REPRESENTATIONS AND WARRANTIES; DISCLAIMER

     5.1. Mutual Warranties. Each party represents and warrants to the other party that
(a) it has all requisite corporate power and authority to enter into this Agreement, to grant the
licenses granted by it hereunder, and to perform its other obligations under this Agreement, (b)
execution of this Agreement and the performance by the warranting party of its obligations
hereunder, including, without limitation, the licenses granted by that party hereunder, have been
duly authorized, and (c) this Agreement is fully binding and enforceable in accordance with its
terms.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-10-

 

     5.2. Licensee Warranties and Covenants. Licensee warrants, represents and covenants
that:

          5.2.1. all of Licensed Entities’ activities related to its use of the Chiron Patent Rights
pursuant to this Agreement shall comply in all material respects with all applicable legal and
regulatory requirements, including, without limitation, all applicable regulatory requirements; and

          5.2.2. no Licensed Entity shall engage in any activities that would infringe the Chiron Patent
Rights and are outside the scope of the Research and Development License to be granted hereunder
(e.g., without limitation, use of the Licensed Processes outside the Licensee Facility or after the
termination of the Research and Development Term); and

          5.2.3. it shall obtain from any [ * ] a written undertaking requiring such [ * ] to perform
the payment obligations referenced in Article 3 herein; and

          5.2.4 that it shall promptly provide Chiron with a copy of such written undertaking described
in Section 5.2.3 above.

     5.3. Chiron Warranties. Chiron represents and warrants to Licensee that, as of the
Effective Date, the [ * ] for all Identified Products [ * ] and [ * ] for
[ * ] Identified Products
[ * ] are [ * ] for certain of the Chiron Patent Rights.

     5.4. DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, CHIRON MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY
EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT
TO THE CHIRON PATENT RIGHTS OR ANY LICENSE GRANTED BY CHIRON HEREUNDER, OR WITH RESPECT TO ANY
PRODUCTS OR SERVICES OF LICENSEE. FURTHERMORE, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A
WARRANTY THAT ANY PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE CHIRON PATENT RIGHTS ARE VALID
OR ENFORCEABLE OR THAT LICENSED ENTITIES’ USE OF THE CHIRON PATENT RIGHTS CONTEMPLATED HEREUNDER
DOES NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.

     5.5. Patent Matters. Chiron shall have the exclusive right to take action against any
infringement of any of the Chiron Patent Rights, in its sole discretion. Licensee shall cooperate
reasonably in any action Chiron may take against any such infringement, upon Chiron’s request and
at Chiron’s expense.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-11-

 

6. LIMITATION OF LIABILITY

NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER
WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT
LIABILITY, OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INCIDENTAL, INDIRECT OR CONSEQUENTIAL
DAMAGES.

7. INDEMNITY

     7.1. Licensee Indemnity. Subject to Section 7.2, Licensee shall indemnify, defend and
hold harmless Chiron and its Affiliates and the officers, directors, employees, agents and
representatives of Chiron and its Affiliates from and against any and all claims, threatened
claims, damages, losses, suits, proceedings or liabilities of any kind (“Claims”) arising out of or
relating to Licensed Entities’ manufacture, use, sale, offering for sale, importation or
exportation of Identified Products or to its use otherwise of the Chiron Patent Rights, including
without limitation, Claims based on product liability or infringement of third party patent or
intellectual property rights, except to the extent any such Claim arises from the negligence or
willful misconduct or material breach of this Agreement by Chiron.

     7.2. Indemnification Procedures. Chiron shall notify Licensee in writing promptly
upon becoming aware of any Claim to which such indemnification may apply. Licensee shall be
relieved of its obligation of indemnification to the extent, and only to the extent, Licensee is
prejudiced by any failure of Chiron to provide Licensee with the foregoing notice of any such Claim
within a reasonable period of time. Licensee shall have the right to assume and control the
defense of the Claim at its own expense. If the right to assume and have sole control of the
defense is exercised by Licensee, Chiron shall have the right to participate in, but not control,
such defense at its own expense and Licensee’s indemnity obligations shall be deemed not to include
attorneys’ fees and litigation expenses incurred by Chiron after the assumption of the defense by
Licensee. If Licensee does not assume the defense of the Claim, Chiron may defend the Claim at
Chiron’s expense but shall have no obligation to do so. Chiron will not settle or compromise the
Claim without the prior written consent of Licensee, and Licensee will not settle or compromise the
Claim in any manner which would have an adverse effect on Chiron without the consent of Chiron,
which consent, in each case, will not be unreasonably withheld. Chiron shall reasonably cooperate
with Licensee and will make available to Licensee all pertinent information under the control of
Chiron.

     7.3. Presumptions and Burden of Proof Regarding Claims of Exempt Product Status. The
parties agree that there shall be a presumption that inhibitor
compounds of (i) the HCV [ * ] or
[ * ] HCV [ * ], or (iii) HCV,
which [ * ] HCV [ * ] arising prior to the expiration of Chiron Patent Rights in the relevant Reference
Country from Licensee’s program for research, development and commercialization of HCV
[ * ] products (a “Product in Question”) are Identified

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-12-

 

Products, and are
subject to the obligations governing Identified Products provided herein. In the event that
Licensee contends that a Product In Question is not an Identified Product (an “Exempt Product”)
Licensee shall have the burden of proving such contention by a  [ * ], and
the provisions of Section 7.4 shall apply.

     7.4. Exempt Product Notification. In the event that Licensee or any Licensee
Affiliate makes an IND submission (or foreign equivalent) for any Product in Question after the
Effective Date which Licensee contends to be an Exempt Product, Licensee shall provide Chiron a
written notice providing particular and sufficient facts which are the basis for such contention
(the “Exempt Product Notification”). Licensee shall provide Chiron with the Exempt Product
Notification within thirty (30) days following IND (or foreign equivalent) filing of any alleged
Exempt Product by Licensee (the “Exempt Product Notification Period”).

In the event that Licensee submits
 to Chiron an Exempt Product Notification, Chiron shall have the
right to [ * ]. In the event that Chiron disputes
Licensee’s claim that the Product in Question is an Exempt Product [ * ], the
dispute shall be governed by the dispute resolution provisions provided herein, provided that the
[ * ] and burden of proof provisions referenced in Section 7.3 shall apply to such dispute
resolution.

In the event that Licensee fails to provide Chiron with an Exempt Product Notification within the
Exempt Product Notification Period,
[ * ].

In the event that a Product In Question is determined by action under this Section 7.4 to qualify
as an Identified Product (provided that such determination is either accepted or no longer subject
to challenge by Licensee under the dispute resolution provisions herein) at a time after the
achievement of a corresponding milestone event for the Product In Question, and in the event the
milestone payment relating to the same was not paid when it was due, any such unpaid milestone
payment shall become immediately due and bear interest for the period of non-payment as provided in
Section 3.2.3 above.

8. TERM AND TERMINATION

     8.1. Research and Development Term. The “Research and Development Term” shall be the
period commencing from the Effective Date and ending on the earlier of (a) the date as of which
Chiron receives Licensee’s notification that Licensee no longer desires to exercise the research
and development License (granted under Section 2.1) and has permanently ceased all use of Licensed
Processes or other activities which fall within the scope of the Chiron Patent Rights, or (b) the
last to expire patent containing a Valid Claim within the Chiron Patent Rights
in the relevant Reference Country in which Licensee or a Licensee Affiliate is conducting
research activities.

     8.2. Payment Term; Expiration. Licensee’s obligation to make milestone payments as
specified in Section 3.1.3, and royalty payments on Net Sales of Identified Products pursuant

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-13-

 

to
Sections 3.1.4 and 3.1.5, shall terminate upon [ * ] (the “Payment Term”). In acknowledgement of
Licensee’s agreement to enter into a deferred payment arrangement instead of paying a fully
negotiable up-front fee for the license to the Chiron Patent Rights referenced herein, Licensee
agrees that Licensee’s obligation to pay milestone and royalty payments as referenced herein shall
be unconditional and irrevocable during the Payment Term, notwithstanding [ * ]. This Agreement
shall expire upon the expiration of the Payment Term. Upon expiration of the Payment Term, all
rights of Licensee hereunder shall automatically become fully paid-up, royalty-free, irrevocable,
fully sublicenseable and perpetual.

     8.3. Termination.

          8.3.1. Chiron shall have the right to terminate this Agreement, at Chiron’s sole discretion,
upon delivery of written notice to Licensee, upon the occurrence of any of the following:

          (a) In the event of any material breach by Licensee of any terms and conditions of this
Agreement, provided that such breach has not been cured within sixty (60) days after written notice
thereof is given by Chiron to Licensee; or

          (b) In the event that Licensee or any [ * ] challenges or knowingly supports (other than
pursuant to a subpoena or other court order) a challenge to the validity of any of the Chiron
Patent Rights. Chiron’s termination rights under this Section 8.3.1(b) may be exercised by Chiron
at any time subsequent to Licensee’s (or any [ * ]) challenge to the validity of the Chiron Patent
Rights.

          8.3.2. Either party shall have the right to terminate this Agreement, upon the filing by the
other party in any court or agency pursuant to any statute or regulation of the United States or
any state a petition in bankruptcy or insolvency or for reorganization or similar arrangement or
for the appointment of a receiver or trustee of such party or its assets, upon the proposal of a
written agreement of composition or extension of its debts, or if such party is served with an
involuntary petition against it in any insolvency proceeding, upon the ninety-first (91st) day
after such service if such involuntary petition has not previously been stayed or dismissed, or
upon the making by such party of an assignment for the benefit of its creditors.

     8.4. Effect of Termination or Expiration.

          8.4.1. In General. Upon termination of this Agreement for any reason:

               (a) All rights and licenses to use Licensed Compositions and Licensed Methods granted to
Licensee in Article 2 shall terminate, and Licensee shall cease all use of Chiron Patent Rights,
provided, however, that Licensee retains all rights and licenses to research,
develop, make, have made, use, have used, sell, have sold, import and export Identified
Products granted to Licensee in Article 2 to the extent that the exercise of such rights does not
infringe any Chiron Patent Rights, subject to Licensee’s obligations under Articles 3, 4 and 7;

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-14-

 

               (b) Chiron shall have the right to obtain specific performance of Licensee’s payment
obligations referenced in Section 3.1, including, without limitation, Licensee’s royalty and
milestone obligations referenced therein;

               (c) Chiron shall have the right to retain all amounts previously paid to Chiron by Licensee;
and

               (d) Neither party shall be relieved of any obligation which accrued prior to the effective
date of such expiration or early termination; in particular, without limitation, Licensee shall
remain obligated to pay to Chiron all amounts which have accrued hereunder as of such date, all in
accordance with Section 3.

          8.4.2. Survival. Except as expressly provided herein, the following provisions shall survive
expiration or termination of this Agreement: Article 1, Article 2 (to the extent provided in
Section 8.4.1 above), Article 3, Article 4, Article 5, Article 6, Article 7, Section 8.2, Article
9, Article 10 and any other provisions which by their nature are intended to survive termination.

9. CONFIDENTIAL INFORMATION

     9.1 Confidentiality. Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing, the parties agree that, for the term of this Agreement and for ten
(10) years thereafter, Chiron (the “Receiving Party”) agrees that with respect to whatever Licensee
Confidential Information it receives from Licensee (the “Disclosing Party”) hereunder, the
Receiving Party shall keep such Licensee Confidential Information confidential and shall not
publish or otherwise disclose or use such Licensee Confidential Information for any purpose other
than as provided for by in this Agreement except for Licensee Confidential Information that the
Receiving Party can establish:

          (a) was already known to the Receiving Party (other than under an obligation of
confidentiality), at the time of disclosure by the Disclosing Party and such Receiving Party has
documentary evidence to that effect;

          (b) was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the Receiving Party;

          (c) became generally available to the public or otherwise part of the public domain after its
disclosure or development, as the case may be, and other than through any act or omission of the
Receiving Party in breach of this confidentiality obligation;

          (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality,
by a third party who had no obligation to the Disclosing Party not to disclose such information to
others; or

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-15-

 

          (e) was independently discovered or developed by or on behalf of the Receiving Party without
the use of the Licensee Confidential Information and the Receiving Party has documentary evidence
to that effect.

     9.2 Authorized Disclosure and Use. Notwithstanding the foregoing Section 9.1, Chiron
may disclose Licensee Confidential Information to the extent such disclosure is required to comply
with a court order or applicable governmental law or regulation, including, without limitation, law
and regulations of the United States Securities and Exchange Commission, the National Association
of Securities Dealers or any national stock exchange regulation, and except as expressly provided
herein. In addition, either party may disclose the terms of this Agreement to its accountants or
attorneys or its potential or actual partners or collaborators under an obligation of
confidentiality no less stringent than that provided in Section 9.1 above. In the event Chiron is
required by court order to disclose Licensee Confidential Information, Chiron shall provide
sufficient notice to Licensee and such reasonable cooperation and assistance to enable Licensee to
seek a protective order or otherwise prevent or limit disclosure or use of such Licensee
Confidential Information.

     9.3 Publicity. Neither Licensee nor Chiron shall make any public announcement
concerning the economic terms of this Agreement without the prior written consent of the other
party. Notwithstanding the foregoing, the parties agree that either party shall have the right to
issue a public announcement regarding the execution of this Agreement following such execution.
The party making such public announcement shall submit the proposed form of such public
announcement to the other party and shall incorporate the other party’s reasonable comments and
suggestions prior to issuance of such public announcement.

10. GENERAL

     10.1. Provisions Contrary to Law. In performing this Agreement, the parties shall
comply with all applicable laws. Wherever there is any conflict between any provision of this
Agreement and any law, the law shall prevail, but in such event the affected provision of this
Agreement shall be limited or eliminated only to the extent necessary, and the remainder of this
Agreement shall remain in full force and effect. In the event the terms of this Agreement are
materially altered as a result of the foregoing, the parties shall renegotiate in good faith the
terms of this Agreement to resolve any inequities.

     10.2. Notices. Any notice required or permitted to be given by this Agreement shall be in
writing and shall be delivered by hand or overnight courier with tracking capabilities or mailed
postage prepaid by first class, registered or certified mail addressed as set forth below unless
changed by notice so given:

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-16-

 

If to Chiron:

Chiron Corporation

4560 Horton Street

Emeryville, California 94068-2916

Attention: President, Chiron BioPharmaceuticals

Fax: (510) 923-3832

Copy to: Office of the General Counsel

Fax: (510) 654-5360

If to Licensee:

InterMune, Inc.

3280 Bayshore Blvd.

Brisbane, California 94005

Attention: General Counsel

Fax: (415) 508-0006

     Any such notice shall be deemed delivered on the date received. In addition to any notices
required or permitted hereunder, the parties shall use the contact information below for purposes
of providing accounting or payment information set forth in Articles 3 and 4 hereof:

If to Chiron:

Chiron Corporation

4560 Horton Street

Emeryville, California 94068-2916

Attention: Manager, R&D Operations

Tel: (510) 923-8128

Fax: (510) 923-8341

If to Licensee:

InterMune, Inc.

3280 Bayshore Blvd.

Brisbane, California 94005

Attention: Chief Financial Officer

Tel: (415) 466-2269

Fax: (415) 466-2369

     10.3. Force Majeure. Neither party shall be liable for delay or failure in the
performance of any of its obligations hereunder if such delay or failure is due to causes beyond
its reasonable control, including, without limitation, acts of God, fires, earthquakes, strikes and
labor disputes, acts of war, civil unrest or intervention of any governmental authority; provided,
that the affected party promptly notifies the other party and further provided that the affected
party shall use its commercially reasonable efforts to avoid or remove such causes of non-

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-17-

 

performance and shall continue performance with the utmost dispatch whenever such causes are
removed. When such circumstances arise, the parties shall negotiate in good faith any
modifications of the terms of this Agreement that may be necessary or appropriate in order to
arrive at an equitable solution.

     10.4. Use of Names. Licensee, at its sole cost and expense, shall be responsible for
the selection, registration and maintenance of all trademarks which it employs in connection with
its activities conducted pursuant to this Agreement, if any, and shall own and control such
trademarks. Nothing in this Agreement shall be construed as a grant to Licensee of rights, by
license or otherwise, to the use of any trademarks, service marks, logos or the name of Chiron for
any purpose. Neither party shall use the name or marks or logos of the other party for any purpose
without the prior written consent of such other party.

     10.5. Assignment. Neither party shall assign its rights or obligations under this Agreement
without the prior written consent of the party, except that (i) Chiron may, without Licensee’s
consent, assign all of its rights and obligations hereunder in connection with any transfer of all
of the Chiron Patent Rights, to any Affiliate of Chiron or another third party, (including, without
limitation, a successor in interest) provided, however, that such Affiliate or assignee or
successor in interest agrees to be bound by the terms of this Agreement; and (ii) Licensee may and
shall assign all of its rights and obligation hereunder to a successor in interest of the entire
business to which this Agreement relates, provided that such successor in interest agrees to be
bound by the terms of this Agreement. Subject to the foregoing, this Agreement shall inure to the
benefit of and be binding on the parties’ permitted successors and assigns.

     10.6. Waivers and Modifications. The failure of any party to insist on the
performance of any obligation hereunder shall not be deemed to be a waiver of such obligation.
Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach
of such provision or any other provision. No waiver, modification, release or amendment of any
obligation under or provision of this Agreement shall be valid or effective unless in writing and
signed by all parties hereto.

     10.7. Choice of Law and Jurisdiction. This Agreement shall be governed by and shall
be construed in accordance with the laws of the State of California without regard to the conflicts
of laws provisions thereof.

     10.8. Dispute Resolution. Any dispute arising out of or in connection with this
Agreement shall be resolved by the parties in the following manner:

          10.8.1. Informal Settlement. Either party may initiate resolution of such controversy
by providing to the other party a brief and concise statement of the initiating party’s claims,
together with relevant facts supporting them, and referring to this Section 10. For a period of
sixty (60) days from the date of such statement, or such longer period as the parties may agree in
writing, the parties shall make good faith efforts to settle the dispute. Such efforts shall
include, without limitation, full presentation of the parties’ respective positions before their
respective designated senior executives.

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-18-

 

          10.8.2. Arbitration. Any controversy or claim arising out of or relating to this Agreement or
the validity, inducement, or breach thereof, shall be settled by binding arbitration before three
arbitrators in accordance with the Commercial Arbitration Rules of the American Arbitration
Association (“AAA”) then pertaining, except where those rules conflict with this provision, in
which case this provision controls. The parties hereby consent to the jurisdiction of the federal
district court for the district in which the arbitration is held for the enforcement of this
provision and the entry of judgment on any award rendered hereunder. Should such court for any
reason lack jurisdiction, any court with jurisdiction shall enforce this clause and enter judgment
on any award. Each arbitrator shall be an attorney who has at least fifteen (15) years of
experience with a law firm or corporate law department of over twenty-five (25) lawyers or was a
judge of a court of general jurisdiction. The arbitration shall be held in San Francisco,
California or such other place as the parties agree, and in rendering the award the arbitrators
must apply the substantive law of California (except where that law conflicts with this clause),
except that the interpretation and enforcement of this arbitration provision shall be governed by
the Federal Arbitration Act. The arbitrators shall be neutral, independent, disinterested,
impartial and shall abide by the Code of Ethics for Arbitrators in Commercial Disputes approved by
the AAA. Within forty-five (45) days of initiation of arbitration, each party shall select its
arbitrator. The third arbitrator shall be mutually agreed upon by the two arbitrators chosen by the
parties. In the event that the two arbitrators cannot agree on a third arbitrator within sixty
(60) days of their approval then AAA shall appoint an arbitrator who shall be an attorney who has
at least fifteen (15) years of experience with a law firm or corporate law department of over
twenty-five (25) lawyers or was a judge of a court of general jurisdiction. The parties shall
reach agreement upon and thereafter follow procedures assuring that the arbitration will be
concluded and the award rendered within no more than eight months from selection of the
arbitrators. Failing such agreement, the AAA will design and the parties will follow procedures
that meet such a time schedule. Each party has the right before or, if the arbitrator cannot hear
the matter within a acceptable period, during the arbitration to seek and obtain from the
appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc.,
to avoid irreparable harm, maintain the status quo or preserve the subject matter of the
arbitration. Notwithstanding the foregoing, either party may seek an order from a court of
competent jurisdiction to restrain the other from violating the nondisclosure provisions of Article
9, the restrictions on use of trademarks in Section 10.4, or the limitations on the use of the
Chiron Patent Rights set forth in Article 2.

     10.9. Entire Agreement. This Agreement and the exhibits hereto constitute the entire
agreement between the parties as to the subject matter hereof, and supersede all prior
negotiations, representations, agreements and understandings regarding the same.

     10.10. Counterparts. This Agreement may be executed in counterparts with the same effect as
if both parties had signed the same document. All such counterparts shall be deemed an original,
shall be construed together and shall constitute one and the same instrument.

     10.11. Relationship of the Parties. Each party is an independent contractor under
this Agreement. Nothing contained herein is intended or is to be construed so as to constitute
Chiron and Licensee as partners, agents or joint venturers. Neither party shall have any express
or implied right or authority to assume or create any obligations on behalf of or in the name of
the

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-19-

 

other party or to bind the other party to any contract, agreement or undertaking with any third
party.

     10.12. Headings. Headings and captions are for convenience only and are not be used in the
interpretation of this Agreement.

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date set forth above.

	 	 	 	 	 	 	 	 	 
	CHIRON CORPORATION	 	 	 	INTERMUNE, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Craig A. Wheeler
	 	 	 	By:
	 	/s/ Thomas Kassberg
	 

	 	 
	 	 	 	 	 	 
	 

	 	Craig A. Wheeler	 	 	 	Name:
	 	Thomas Kassberg
	 

	 	President, Chiron BioPharmaceuticals
	 	 	 	Title:
	 	Sr. VP Business Development
	 

	 	 	 	 	 	 	 	 

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-20-

 

EXHIBIT A

Patents Relating to HCV

[ * ]

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-21-

 

EXHIBIT B

Location(s) of Licensee Facility(ies)

InterMune, Inc., 3280 Bayshore Boulevard, Brisbane, CA 94005

[ * ]

[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-22-

 

EXHIBIT C

Identified Product(s) and Latest Stage of Clinical Achievement for each such Identified

Product arising from Licensee’s Prior Activity

(None)

 

			
	[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

-23-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]